Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135106 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL8513273 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL5696388 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL197791 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL197425 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| SCHEMBL1226045 | 1.00 | KCNH2 (0.56) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL5513962 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL11235696 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL8870650 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A | |
| Hydrochloric Acid SCHEMBL8870646 | 0.98 | KCNH2 (0.55) | KCNH2SCN3ADPP4SCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1174 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800829-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-10-13 | — | — | US | claimed |
| CN-110036009-A | Substituted pyrrolidines and their use in the treatment of cystic fibrosis | 艾伯维公司 | 2019-07-19 | — | — | CN | claimed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | claimed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-20160076058-A1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | GENOMATICA, INC. | 2016-03-17 | — | — | US | claimed |
| CN-102812003-B | Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43) | EUROSCREEN SA | 2015-01-21 | — | — | CN | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | US | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| EP-2160460-A2 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | LS9, Inc. (US) | 2010-03-10 | — | — | EP | claimed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| WO-2008147781-A2 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | LS9, INC. (US) | 2008-12-04 | — | — | WO | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12584119-B2 | Variant alpha-amylases having amino acid substitutions that lower the PKA of the general acid | DANISCO US INC (US) | 2026-03-24 | — | — | US | disclosed |
| US-12577548-B2 | Alpha-amylase combinatorial variants | DANISCO US INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12559738-B2 | Glucoamylase and methods of use thereof | DANISCO US INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260049296-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4153310-B1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 PHARMA GMBH (AT) | 2026-02-18 | — | — | EP | disclosed |
| US-12553883-B2 | Methods and uses of microbiome compositions | MarvelBiome, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12509670-B2 | Glucoamylase and methods of use thereof | DANISCO US INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3601553-B1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12480110-B2 | Alpha-amylase combinatorial variants | DANISCO US INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250339560-A1 | GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | AKOUOS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340855-A1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250288692-A1 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | AKOUOS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250279166-A1 | A METHOD FOR MEASURING GALACTOOLIGOSACCHARIDES | DUPONT NUTRITION BIOSCI APS (DK) | 2025-09-04 | — | — | US | disclosed |
| EP-4389885-B1 | ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270575-A1 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | NEOPLANTS SAS (FR) | 2025-08-28 | — | — | US | disclosed |
| US-12383615-B2 | Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods | CARBON BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250236858-A1 | GLUCOAMYLASE VARIANTS AND METHODS FOR USE THEREOF | DANISCO US INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12365726-B2 | Anti-VEGF antibody constructs | AKOUOS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250228277-A1 | MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE | MarvelBiome, Inc. | 2025-07-17 | — | — | US | disclosed |
| US-20250223349-A1 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | AKOUOS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250222137-A1 | GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | AKOUOS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250223350-A1 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | AKOUOS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-2825643-B2 | VARIANT ALPHA AMYLASES WITH ENHANCED ACTIVITY ON STARCH POLYMERS | DANISCO US INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250213604-A1 | TARGETED DELIVERY | JUDO BIO INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-12338467-B2 | Variant maltohexaose-forming α-amylase variants | DANISCO US INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250177513-A1 | RABIES G PROTEIN AND USES THEREOF | ICOSAVAX, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-2859097-B2 | ALPHA-AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASEI(CSPAMY2). | DANISCO US INC (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4548766-A2 | IMPROVED ENZYMATIC MODIFICATION OF PHOSPHOLIPIDS IN FOOD | International N&H Denmark ApS (DK) | 2025-05-07 | — | — | EP | disclosed |
| US-20250136673-A1 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | AKOUOS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250123271-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS | MarvelBiome, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4026902-B1 | VARIANT ALPHA AMYLASES WITH ENHANCED ACTIVITY ON STARCH POLYMERS | DANISCO US INC (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3336183-B2 | ALPHA-AMYLASE CONBINATORIAL VARIANTS | DANISCO US INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250066754-A1 | ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-3728573-B1 | IMPROVED ENZYMATIC MODIFICATION OF PHOSPHOLIPIDS IN FOOD | INT N&H DENMARK APS (DK) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042955-A1 | REDUCTION OF ACETATE AND GLYCEROL IN MODIFIED YEAST HAVING AN EXOGENOUS ETHANOL-PRODUCING PATHWAY | DANISCO US INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20250043265-A1 | HYBRID CLUCOAMYLASES AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20250008966-A1 | IMPROVED ENZYMATIC MODIFICATION OF GALACTOLIPIDS IN FOOD | INT N&H DENMARK APS (DK) | 2025-01-09 | — | — | US | disclosed |
| US-20250002907-A1 | STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF | UNIVERSITY OF WASHINGTON | 2025-01-02 | — | — | US | disclosed |
| EP-4483721-A2 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | Danisco US Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240400622-A1 | GENETICALLY ENCODED VOLTAGE INDICATORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240401011-A1 | IMPROVED LIPASE FOR DEFOAMING | DANISCO US INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-3371307-B1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | DANISCO US INC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240376457-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240358820-A1 | PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODS | CARBON BIOSCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12129465-B2 | Stable coronavirus proteins and vaccine compositions thereof | UNIVERSITY OF WASHINGTON (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240350616-A1 | VIRUS-LIKE PARTICLE VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS | ICOSAVAX, INC. | 2024-10-24 | — | — | US | disclosed |
| EP-4442832-A2 | MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240327814-A1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240318129-A1 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | NEOPLANTS SAS (FR) | 2024-09-26 | — | — | US | disclosed |
| WO-2024197242-A1 | PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODS | CARBON BIOSCIENCES, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-3699271-B1 | GRANULE AND PELLET COMPOSITIONS COMPRISING PHYTASE AND PHYTIC ACID AND PREPARATION METHOD | DANISCO US INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240299494-A1 | METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTOR | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240299471-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-12084694-B2 | Alpha-amylase variants | DANISCO US INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240252621-A1 | VIRUS-LIKE PARTICLE VACCINE FOR CORONAVIRUS | ICOSAVAX, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240252685-A1 | CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | AKOUOS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4389885-A2 | ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3891267-B1 | MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE | MARVELBIOME INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240167056-A1 | CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | AKOUOS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11980654-B2 | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240139344-A1 | COMPOSITIONS AND METHODS FOR TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS | AKOUOS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11957723-B2 | Methods and uses of microbiome compositions, components, or metabolites for treating neurodegenerative diseases | MarvelBiome, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240108021-A1 | MODIFICATION OF STEVIOL GLYCOSIDES BY GLUCOSYLTRANSFERASE ENZYMES | INTERNATIONAL N&H DENMARK APS (DK) | 2024-04-04 | — | — | US | disclosed |
| EP-4345161-A2 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-20240081351-A1 | ENZYMATIC MODIFICATION OF PHOSPHOLIPIDS IN FOOD | INTERNATIONAL N&H DENMARK APS (DK) | 2024-03-14 | — | — | US | disclosed |
| US-20240076665-A1 | REGULATORY ELEMENTS FOR SCHWANN CELL-SPECIFIC GENE EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-07 | — | — | US | disclosed |
| US-11920170-B2 | Alpha-amylase combinatorial variants | DANISCO US INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240066075-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11898177-B2 | Variant maltohexaose-forming alpha-amylase variants | DANISCO US INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3967757-B1 | ALPHA-AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASE (CSPAMY2). | DANISCO US INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20230404088-A1 | COMBINATION OF NONMALTOGENIC EXOAMYLASE AND GLUCOAMYLASE FOR IMPROVING BREAD RESILIENCE AND REDUCING AMOUNT OF ADDED SUGARS | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2023-12-21 | — | — | US | disclosed |
| US-20230348879-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2023-11-02 | — | — | US | disclosed |
| EP-4267199-A1 | REGULATORY ELEMENTS FOR SCHWANN CELL-SPECIFIC GENE EXPRESSION | Wisconsin Alumni Research Foundation (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230340444-A1 | GLUCOAMYLASE AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4262763-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | Council of Scientific & Industrial Research (IN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4248757-A2 | IMPROVED ENZYMATIC MODIFICATION OF PHOSPHOLIPIDS IN FOOD | DuPont Nutrition Biosciences ApS (DK) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | F4 PHARMA GMBH (AT) | 2023-09-21 | — | — | US | disclosed |
| US-20230295287-A1 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | AKOUOS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11744254-B2 | Enzymatic modification of phospholipids in food | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2023-09-05 | — | — | US | disclosed |
| EP-2268804-B2 | HEMICELLULASE ENRICHED COMPOSITIONS FOR ENHANCING HYDROLYSIS OF BIOMASS | DANISCO US INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230227803-A1 | ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230212788-A1 | NEW METHOD FOR AUTOMATED ON-DEMAND BIOMOLECULAR ARRAY SYNTHESIS | Technische Universität Dresden (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212606-A1 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | AKOUOS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230201372-A1 | COMPOSITIONS AND METHODS FOR TREATING SLC26A4-ASSOCIATED HEARING LOSS | AKOUOS, INC. | 2023-06-29 | — | — | US | disclosed |
| CN-116348128-A | Bβ15-42 for treating viral endopdermatitis | F4医药有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230190709-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230183743-A1 | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS | AKOUOS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230174962-A1 | VARIANT ALPHA-AMYLASES HAVING AMINO ACID SUBSTITUTIONS THAT LOWER THE PKA OF THE GENERAL ACID | DANISCO US INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230176038-A1 | Methods for Identifying Modulators of Insect Transient Receptor Potential Channels | BASF CORP (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4153310-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 Pharma GmbH (AT) | 2023-03-29 | — | — | EP | disclosed |
| US-20230087305-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. | 2023-03-23 | — | — | US | disclosed |
| EP-2859097-B9 | ALPHA-AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASEI(CSPAMY2). | DANISCO US INC (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4141113-A1 | PAENIBACILLUS SP. MANNANASES | Danisco US Inc (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20230055224-A1 | IMPROVED LIPASE FOR DEFOAMING | DANISCO US INC (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| EP-4127718-A1 | NEW METHOD FOR AUTOMATED ON-DEMAND BIOMOLECULAR ARRAY SYNTHESIS | Technische Universität Dresden (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115698714-A | Novel method for automated on-demand biomolecule array synthesis | 德累斯顿工业大学 | 2023-02-03 | — | — | CN | disclosed |
| US-20230002749-A1 | THERMOSTABLE GLUCOAMYLASE AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220396806-A1 | METHODS OF TREATING HEARING LOSS USING A SECRETED TARGET PROTEIN | AKOUOS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220396783-A1 | GLUCOAMYLASE AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11525151-B2 | Glucoamylases and methods of use, thereof | DANISCO US INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
| US-20220349017-A1 | REAGENTS AND METHODS FOR DETECTING AAV SHEDDING | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4081036-A1 | METHODS FOR IDENTIFYING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF CORPORATION (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220330597-A1 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | MarvelBiome, Inc. | 2022-10-20 | — | — | US | disclosed |
| US-20220325279-A1 | STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220325307-A1 | USE OF LACTASE TO PROVIDE HIGH GOS FIBER LEVEL AND LOW LACTOSE LEVEL | INTERNATIONAL N&H DENMARK APS (DK) | 2022-10-13 | — | — | US | disclosed |
| EP-4071763-A1 | A METHOD FOR MEASURING GALACTOOLIGOSACCHARIDES | DuPont Nutrition Biosciences ApS (DK) | 2022-10-12 | — | — | EP | disclosed |
| US-11441139-B2 | α-Amylase variants | DANISCO US INC (157111) (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220256823-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME | MarvelBiome, Inc. | 2022-08-18 | — | — | US | disclosed |
| US-20220259528-A1 | ENZYMES FOR INFUSION MASHING IN ADJUNCT BREWING TECHNICAL FIELD | INTERNATIONAL N&H DENMARK APS (DK) | 2022-08-18 | — | — | US | disclosed |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-4026902-A1 | VARIANT ALPHA AMYLASES WITH ENHANCED ACTIVITY ON STARCH POLYMERS | Danisco US Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022140521-A1 | REGULATORY ELEMENTS FOR SCHWANN CELL-SPECIFIC GENE EXPRESSION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022130411-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | disclosed |
| US-20220168390-A1 | METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTOR | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-06-02 | — | — | US | disclosed |
| US-20220162657-A1 | GLUCOAMYLASES AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3371308-B1 | PAENIBACILLUS SP. MANNANASES | DANISCO US INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20220136027-A1 | PROTEIN HYDROLYSATES WITH INCREASED YIELD OF N-TERMINAL AMINO ACID | INTERNATIONAL N&H DENMARK APS (DK) | 2022-05-05 | — | — | US | disclosed |
| EP-3978604-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | Danisco US Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11284609-B2 | Compositions and methods for characterizing a microbiome | MarvelBiome, Inc. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220082552-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS | MarvelBiome, Inc. | 2022-03-17 | — | — | US | disclosed |
| EP-3967757-A1 | ALPHA-AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASE (CSPAMY2). | Danisco US Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11267874-B2 | Sensor systems for target ligands and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220022508-A1 | MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE | MarvelBiome, Inc. | 2022-01-27 | — | — | US | disclosed |
| US-20220002696-A1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2022-01-06 | — | — | US | disclosed |
| EP-2970930-B2 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210371901-A1 | Kits and Methods for Detecting Methylated DNA | SEQUENOM, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210371836-A1 | Methods And Compositions Related To Thioesterase Enzymes | GENOMATICA, INC. | 2021-12-02 | — | — | US | disclosed |
| WO-2021233971-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-25 | — | — | WO | disclosed |
| EP-3912679-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-24 | — | — | EP | disclosed |
| US-20210355469-A1 | ALPHA-AMYLASES WITH MUTATIONS THAT IMPROVE STABILITY IN THE PRESENCE OF CHELANTS | DANISCO US INC. | 2021-11-18 | — | — | US | disclosed |
| EP-2859097-B1 | ALPHA-AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASEI(CSPAMY2). | DANISCO US INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-2825643-B1 | VARIANT ALPHA AMYLASES WITH ENHANCED ACTIVITY ON STARCH POLYMERS | DANISCO US INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210337252-A1 | Means and Methods for Detecting Methylated DNA | SEQUENOM, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3901257-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | Danisco US Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021191247-A1 | NEW METHOD FOR AUTOMATED ON-DEMAND BIOMOLECULAR ARRAY SYNTHESIS | Technische Universität Dresden (DE) | 2021-09-30 | — | — | WO | disclosed |
| US-11122828-B2 | Microbial compositions comprising ellagitannin and methods of use | MarvelBiome, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210282422-A1 | USE OF GLUCOSYL TRANSFERASE TO PROVIDE IMPROVED TEXTURE IN FERMENTED MILK BASED PRODUCTS | INTERNATIONAL N&H DENMARK APS (DK) | 2021-09-16 | — | — | US | disclosed |
| EP-3453711-B1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| EP-3845641-A1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | Danisco US Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2021133566-A1 | METHODS FOR IDENTIFYING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210189363-A1 | ALPHA-AMYLASE VARIANTS | DANISCO US INC | 2021-06-24 | — | — | US | disclosed |
| US-11021695-B2 | Methods and compositions related to thioesterase enzymes | GENOMATICA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3087391-B1 | METHODS FOR DETERMINING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL V (TRPV) CHANNEL | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3311172-B1 | METHODS FOR IDENTIFYING COMPOUNDS THAT DIRECTLY BIND TO INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF SE (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3387124-B1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3336183-B1 | ALPHA-AMYLASE CONBINATORIAL VARIANTS | DANISCO US INC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20210095268-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC | 2021-04-01 | — | — | US | disclosed |
| US-20210076688-A1 | ENZYMATIC MODIFICATION OF PHOSPHOLIPIDS IN FOOD | INTERNATIONAL N&H DENMARK APS (DK) | 2021-03-18 | — | — | US | disclosed |
| US-20210076649-A1 | COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME | MarvelBiome, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210047660-A1 | COMPOSITIONS AND METHODS FOR INCREASING ETHANOL PRODUCTION BY YEAST USING GCY1 AND DAK1 | DANISCO US INC | 2021-02-18 | — | — | US | disclosed |
| US-20210040523-A1 | GLUCOAMYLASES AND METHODS OF USE, THEREOF | DANISCO US INC | 2021-02-11 | — | — | US | disclosed |
| EP-3555295-B1 | BIFUNCTIONAL PHOSPHOKETOLASE-PHOSPHOTRANSACETYLASE FUSION POLYPEPTIDES | DANISCO US INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200377559-A1 | REDUCTION OF ACETATE AND GLYCEROL IN MODIFIED YEAST HAVING AN EXOGENOUS ETHANOL-PRODUCING PATHWAY | DUPONT INDUSTRIAL BIOSCIENCES USA, LLC | 2020-12-03 | — | — | US | disclosed |
| US-20200362324-A1 | PAENIBACILLUS SP. MANNANASES | DANISCO US INC (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10800829-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-10-13 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200277632-A1 | GLUCOAMYLASE AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277590-A1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | DANISCO US INC (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3699271-A1 | GRANULE AND PELLET COMPOSITIONS COMPRISING PHYTASE AND PHYTIC ACID AND PREPARATION METHOD | Danisco US Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-2812429-B1 | GLYCOSYLATION AS A STABILIZER FOR PHYTASE | DANISCO US INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216787-A1 | RIBOFLAVINASE ENZYMES AND THEIR USE TO PREVENT OFF FLAVOR IN BREWING | INTERNATIONAL N&H DENMARK APS (DK) | 2020-07-09 | — | — | US | disclosed |
| EP-3104717-B1 | SUCROSE REDUCTION AND GENERATION OF INSOLUBLE FIBER IN JUICES | DANISCO US INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10654907-B2 | Methods and compositions for producing a cell expressing a T cell receptor | UNIVERSITY HEALTH NETWORK (CA) | 2020-05-19 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-20200138075-A1 | MICROBIAL COMPOSITIONS COMPRISING ELLAGITANNIN AND METHODS OF USE | MarvelBiome, Inc. | 2020-05-07 | — | — | US | disclosed |
| US-20200123218-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3212776-B1 | COMPOSITIONS AND METHODS RELATED TO BETA-GLUCOSIDASE | DANISCO US INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20200102593-A1 | Kits and Methods for Detecting Methylated DNA | SEQUENOM, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| EP-2811844-B1 | METHOD FOR IMPROVEMENT OF STABILITY OF PHYTASE WITH PHYTIC ACID, AND COMPOSITIONS COMPRISING PHYTASE AND PHYTIC ACID | DANISCO US INC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10596245-B2 | Staphylococcus aureus materials and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200087644-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3158338-B1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | HARVARD COLLEGE (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| US-20200056216-A1 | COMPOSITIONS AND METHODS RELATED TO BETA-GLUCOSIDASE | DANISCO US INC (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3572505-A2 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | Danisco US Inc. (US) | 2019-11-27 | — | — | EP | disclosed |
| EP-3564345-A1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | REG Life Sciences, LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10457715-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457924-B2 | Variant maltohexaose-forming alpha-amylase variants | DANISCO US INC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3071691-B1 | VARIANT ALPHA-AMYLASES HAVING REDUCED SUSCEPTIBILITY TO PROTEASE CLEAVAGE, AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2019193062-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE | ABBVIE S.Á.R.L (LU) | 2019-10-10 | — | — | WO | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3166419-B1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | DANISCO US INC (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3099708-B1 | METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR | UNIV HEALTH NETWORK (CA) | 2019-09-04 | — | — | EP | disclosed |
| EP-3523277-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | disclosed |
| CN-110036009-A | Substituted pyrrolidines and their use in the treatment of cystic fibrosis | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| US-10352945-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3060659-B1 | ALPHA-AMYLASES FROM EXIGUOBACTERIUM, AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20190153417-A1 | PAENIBACILLUS SP. MANNANASES | DANISCO US INC | 2019-05-23 | — | — | US | disclosed |
| US-10294466-B2 | Alpha-glucosidase, compositions and methods | DANISCO US INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190144842-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC | 2019-05-16 | — | — | US | disclosed |
| EP-2382285-B1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | REG LIFE SCIENCES LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10266566-B2 | Protease-resistant peptide ligands | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2019067887-A1 | ENAC INHIBITOR PEPTIDES AND USES THEREOF | Spyryx Biosciences, Inc. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20190093089-A1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | GENOMATICA, INC. | 2019-03-28 | — | — | US | disclosed |
| EP-3453711-A1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | The Regents of the University of California (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10227390-B2 | Stabilized polypeptide insulin receptor modulators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190048378-A1 | HEMICELLULASE ENRICHED COMPOSITIONS FOR ENHANCING HYDROLYSIS OF BIOMASS | DANISCO US INC (US) | 2019-02-14 | — | — | US | disclosed |
| US-10188699-B2 | CAPCNA peptide therapeutics for cancer | RLL LLC (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-20190000951-A1 | STAPHYLOCOCCUS AUREUS MATERIALS AND METHODS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2019-01-03 | — | — | US | disclosed |
| US-20180354918-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2018-12-13 | — | — | US | disclosed |
| US-20180320158-A1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | DANISCO US INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10080790-B2 | Staphylococcus aureus materials and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3052622-B1 | ALPHA-AMYLASES FROM A SUBSET OF EXIGUOBACTERIUM, AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3371307-A1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | Danisco US Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180220653-A1 | Methods for Identifying Compounds that Directly Bind to Insect Transient Receptor Potential Channels | BASF SE (DE) | 2018-08-09 | — | — | US | disclosed |
| EP-2753626-B1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180220176-A1 | Means and Methods for Detecting Methylated DNA | SEQUENOM, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-10024845-B2 | Methods for determining modulators of insect transient receptor potential V (TRPV) channel | BASF SE (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10017468-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3336183-A1 | ALPHA-AMYLASE CONBINATORIAL VARIANTS | Danisco US Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180163191-A1 | Alpha-Amylase Combinatorial Variants | DANISCO US INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9986740-B2 | Methods of identifying insect-TRPA1 modulators | BRANDEIS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180147273-A1 | METHODS FOR DISPLAYING POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148704-A1 | POLYPEPTIDES HAVING BETA-MANNANASE ACTIVITY AND METHODS OF USE | DANISCO US INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180118818-A1 | SENSOR SYSTEMS FOR TARGET LIGANDS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180112203-A1 | AMYLASE WITH MALTOGENIC PROPERTIES | DANISCO US INC. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3311172-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT DIRECTLY BIND TO INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF SE (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-2970930-B1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9951322-B2 | Methods and compositions related to thioesterase enzymes | REG Life Sciences, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2018065921-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | WO | disclosed |
| US-9894917-B2 | Glycosylation as a stabilizer for phytase | DANISCO US INC (US) | 2018-02-20 | — | — | US | disclosed |
| US-9890374-B2 | Thermostable carbonic anhydrases and methods of use thereof | DANISCO US INC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180031572-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9879245-B2 | Polypeptides having beta-mannanase activity and methods of use | DANISCO US INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9873919-B2 | Reagents for detecting methylated DNA | SEQUENOM, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20180016563-A1 | ALPHA-GLUCOSIDASE, COMPOSITIONS & METHODS | DANISCO US INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180002683-A1 | ENGINEERED MULTIFUNCTIONAL ENZYMES AND METHODS OF USE | DANISCO US INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170362621-A1 | ENGINEERED MULTIFUNCTIONAL ENZYMES AND METHODS OF USE | DANISCO US INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170349922-A1 | COMPOSITIONS AND METHODS RELATED TO BETA-GLUCOSIDASE | DANISCO US INC. | 2017-12-07 | — | — | US | disclosed |
| EP-2970931-B1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9833503-B2 | Methods for displaying polypeptides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3246404-A1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | Danisco US Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2958902-B1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170313757-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-02 | — | — | US | disclosed |
| EP-3234118-A1 | ENGINEERED MULTIFUNCTIONAL ENZYMES AND METHODS OF USE | Danisco US Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9791455-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170292121-A1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | AGAIN BIO APS (DK) | 2017-10-12 | — | — | US | disclosed |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2017-10-05 | — | — | US | disclosed |
| EP-2513053-B1 | Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders | OGEDA SA (BE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2007416-B1 | PARATYROID HORMONE (PTH) FOR USE IN THE TREATMENT OF ISCHEMIA | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-2268804-B1 | HEMICELLULASE ENRICHED COMPOSITIONS FOR ENHANCING HYDROLYSIS OF BIOMASS | DANISCO US INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2913057-B1 | Cancer peptide therapeutics | UNIV INDIANA RES & TECH CORP (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170246284-A1 | STAPHYLOCOCCUS AUREUS MATERIALS AND METHODS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS | 2017-08-31 | — | — | US | disclosed |
| EP-3008081-B1 | STABILIZED POLYPEPTIDE INSULIN RECEPTOR MODULATORS | HARVARD COLLEGE (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2922951-B1 | AMYLASE WITH MALTOGENIC PROPERTIES | DANISCO US INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170233707-A1 | COMPOSITIONS COMPRISING BETA-MANNANASE AND METHODS OF USE | DANISCO US INC (US) | 2017-08-17 | — | — | US | disclosed |
| EP-2929023-B1 | COMPOSITIONS AND METHODS OF USE | DANISCO US INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170226494-A1 | COMPOSITIONS COMPRISING BETA-MANNANASE AND METHODS OF USE | DANISCO US INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170218351-A1 | COMPOSITIONS COMPRISING BETA-MANNANASE AND METHODS OF USE | DANISCO US INC. (US) | 2017-08-03 | — | — | US | disclosed |
| EP-2160460-B1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | REG LIFE SCIENCES LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170211052-A1 | COMPOSITIONS COMPRISING BETA MANNANASE AND METHODS OF USE | DANISCO US INC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170211054-A1 | COMPOSITIONS COMPRISING BETA MANNANASE AND METHODS OF USE | DANSICO US INC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170211053-A1 | COMPOSITIONS COMPRISING BETA MANNANASE AND METHODS OF USE | DANISCO US INC (US) | 2017-07-27 | — | — | US | disclosed |
| EP-2683817-B1 | THERMOSTABLE CARBONIC ANHYDRASES AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9695120-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2017-07-04 | — | — | US | disclosed |
| US-20170157210-A1 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER | RLL LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170159036-A1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | DANISCO US INC. | 2017-06-08 | — | — | US | disclosed |
| WO-2017079756-A1 | PAENIBACILLUS AND BACILLUS SPP. MANNANASES | DANISCO US INC (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-3158338-A2 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | President and Fellows of Harvard College (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9617325-B2 | Treatment of IgE-mediated disease | BOSTON MEDICAL CENTER CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170081653-A1 | THERMOSTABLE CARBONIC ANHYDRASES AND METHODS OF USE THEREOF | DANISCO US INC. | 2017-03-23 | — | — | US | disclosed |
| EP-2054434-B1 | MYOSTATIN ANTAGONISTS | MYOSTIN THERAPEUTICS PTY LTD (AU) | 2017-03-15 | — | — | EP | disclosed |
| US-9587231-B2 | Methods and compositions related to thioesterase enzymes | REG Life Sciences, LLC (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170037387-A1 | ALPHA AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASE (CSPAMY2) | DANISCO US INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170006871-A1 | METHODS OF IDENTIFYING INSECT-TRPA1 MODULATORS | BRANDEIS UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170006902-A1 | STRATEGY FOR SUCROSE REDUCTION AND GENERATION OF INSOLUBLE FIBER IN JUICES | DANISCO US INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170009219-A1 | Variant Maltohexaose-Forming Alpha-Amylase Variants | DANISCO US INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170003279-A1 | Methods for Determining Modulators of Insect Transient Receptor Potential V (TRPV) Channel | BASF SE (DE) | 2017-01-05 | — | — | US | disclosed |
| US-9527895-B2 | CAPCNA peptide therapeutics for cancer | US ARMY, SECRETARY OF THE ARMY | 2016-12-27 | — | — | US | disclosed |
| WO-2016203014-A1 | METHODS FOR IDENTIFYING COMPOUNDS THAT DIRECTLY BIND TO INSECT TRANSIENT RECEPTOR POTENTIAL CHANNELS | BASF SE (DE) | 2016-12-22 | — | — | WO | disclosed |
| EP-2771458-B1 | VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTS | DANISCO US INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9518103-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-12-13 | — | — | US | disclosed |
| EP-3099708-A1 | METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR | University Health Network (CA) | 2016-12-07 | — | — | EP | disclosed |
| US-20160347860-A1 | ANTIBODIES THAT BIND NOVEL PCSK9 VARIANTS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160340403-A1 | METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR | UNIVERSITY HEALTH NETWORK (CA) | 2016-11-24 | — | — | US | disclosed |
| EP-2929022-B1 | COMPOSITIONS AND METHODS OF USE | DANISCO US INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9488640-B2 | Methods of identifying insect-TRPA1 modulators | BRANDEIS UNIVERSITY (US) | 2016-11-08 | — | — | US | disclosed |
| EP-3087391-A2 | METHODS FOR DETERMINING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL V (TRPV) CHANNEL | BASF SE (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160298157-A1 | COMPOSITIONS COMPRISING A BETA-GLUCOSIDASE POLYPEPTIDE AND METHODS OF USE | DANISCO US INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160272957-A1 | VARIANT ALPHA-AMYLASES HAVING REDUCED SUSCEPTIBILITY TO PROTEASE CLEAVAGE, AND METHODS OF USE, THEREOF | DANISCO US INC. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-1848735-B1 | POLYPEPTIDES HAVING ALPHA-AMYLASE AND GRANULAR STARCH HYDROLYZING ACTIVITY | GENENCOR INT (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9410140-B2 | Thermostable carbonic anhydrases and methods of use thereof | DANISCO US INC (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160215036-A1 | STABILIZED POLYPEPTIDE INSULIN RECEPTOR MODULATORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160201113-A1 | KITS AND METHODS FOR DETECTING METHYLATED DNA | KLINIKUM DER UNIVERSITAET REGENSBURG (DE) | 2016-07-14 | — | — | US | disclosed |
| US-20160186221-A1 | COMPOSITIONS AND METHODS OF USE | DANISCO US INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160186102-A1 | ALPHA-AMYLASES FROM EXIGUOBACTERIUM, AND METHODS OF USE, THEREOF | DANISCO US INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2016100825-A1 | ENGINEERED MULTIFUNCTIONAL ENZYMES AND METHODS OF USE | DANISCO US INC (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160159859-A1 | PROTEASE-RESISTANT PEPTIDE LIGANDS | NORTH CAROLINA STATE UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-20160160199-A1 | ALPHA-AMYLASES FROM EXIGUOBACTERIUM, AND METHODS OF USE, THEREOF | DANISCO US INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160130571-A1 | Alpha-Amylase from Bacillaceae Family Member | DANISCO US INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160115465-A1 | COMPOSITIONS AND METHODS OF USE | DANISCO US INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160096883-A1 | GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016044588-A1 | STAPHYLOCOCCUS AUREUS MATERIALS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160076058-A1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | GENOMATICA, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20160060665-A1 | HEMICELLULASE ENRICHED COMPOSITIONS FOR ENHANCING HYDROLYSIS OF BIOMASS | DANISCO US INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160046914-A1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | GENOMATICA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9249464-B2 | Kits and methods for detecting methylated DNA | SEQUENOM, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20160017303-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160017304-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160017305-A1 | ALPHA-AMYLASE COMBINATORIAL VARIANTS | DANISCO US INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160002185-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2958902-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150369740-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2015195769-A2 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150344923-A1 | COMPOSITIONS AND METHODS OF USE | DANISCO US INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344922-A1 | COMPOSITIONS AND METHODS OF USE | DANISCO US INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344858-A1 | NOVEL MANNANASE, COMPOSITIONS AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9200299-B2 | Genetically engineered cell encoding ole amino acid motifs in a carbon source producing aliphatic ketones or olefins | REG Life Sciences, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9175234-B2 | Methods and compositions related to thioesterase enzymes | REG Life Sciences, LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150285820-A1 | OPTOGENETIC PROBES FOR MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150275255-A1 | Endoglucanase For Reducing The Viscosity Of A Plant Materials Slurry | DANISCO US INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9145462-B2 | Glioblastoma multiforme-reactive antibodies and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150267263-A1 | MEANS AND METHODS FOR DETECTING METHYLATED DNA | KLINIKUM DER UNIVERSITAT REGENSBURG (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150252344-A1 | BETA-GLUCOSIDASE FROM NEUROSPORA CRASSA | DANISCO US INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252343-A1 | BETA-GLUCOSIDASE FROM MAGNAPORTHE GRISEA | DANISCO US INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252340-A1 | COMPOSITIONS AND METHODS OF US | DANISCO US INC. (US) | 2015-09-10 | — | — | US | disclosed |
| EP-2644187-B1 | Alpha-glucanase and oral care composition containing the same | DANISCO US INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2147104-B1 | USE OF AN ASPARTIC PROTEASE (NSP24) SIGNAL SEQUENCE FOR HETEROLOGOUS PROTEIN EXPRESSION | DANISCO US INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2913057-A1 | Cancer peptide therapeutics | Indiana University Research and Technology Corporation (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2015113140-A1 | METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR | UNIVERSITY HEALTH NETWORK (CA) | 2015-08-06 | — | — | WO | disclosed |
| US-9074013-B2 | Means and methods for detecting methylated DNA | SEQUENOM, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150183848-A1 | TREATMENT OF lge-MEDIATED DISEASE | BOSTON MEDICAL CENTER CORPORATION (US) | 2015-07-02 | — | — | US | disclosed |
| WO-2015097560-A2 | METHODS FOR DETERMINING MODULATORS OF INSECT TRANSIENT RECEPTOR POTENTIAL V (TRPV) CHANNEL | BASF SE (DE) | 2015-07-02 | — | — | WO | disclosed |
| EP-2035445-B1 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-17 | — | — | EP | disclosed |
| US-9057734-B2 | Optogenetic probes for measuring membrane potential | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150152401-A1 | ALPHA AMYLASE VARIANTS DERIVED FROM THE ALPHA AMYLASE OF CYTOPHAGA SP. AMYLASE (CSPAMY2) | DANISCO US INC. (US) | 2015-06-04 | — | — | US | disclosed |
| CN-101068922-B | Trichoderma reesei glucoamylase and homologs thereof | GENENCOR INT | 2015-06-03 | — | — | CN | disclosed |
| US-20150141316-A1 | VARIANT ALPHA AMYLASES WITH ENHANCED ACTIVITY ON STARCH POLYMERS | DANISCO US INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150132334-A1 | METHODS FOR DISPLAYING POLYPEPTIDES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| EP-2860195-A1 | Treatment of IgE-mediated disease | Boston Medical Center Corporation (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20150093805-A1 | POLYPEPTIDES HAVING ALPHA-AMYLASE AND GRANULAR STARCH HYDROLYZING ACTIVITY | DANISCO US INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8986970-B2 | Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof | DANISCO US INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-1591530-B1 | A tumor necrosis factor related ligand | BIOGEN IDEC INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2536832-B1 | AMYLASE FROM NESTERENKONIA AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2507266-B1 | TREATMENT OF IgE-MEDIATED DISEASE | BOSTON MEDICAL CT CORP (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20150044736-A1 | FUNGAL CUTINASE FROM MAGNAPORTHE GRISEA | DANISCO US INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8951736-B2 | Multimer glycosylated nucleic acid binding protein conjugates and uses thereof | SEQUENOM, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150037491-A1 | Phytic Acid as a Stabilizer for Phytase | DANISCO US INC (US) | 2015-02-05 | — | — | US | disclosed |
| US-8945575-B2 | Treatment of IgE-mediated disease | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20150030717-A1 | GLYCOSYLATION AS A STABILIZER FOR PHYTASE | DANISCO US INC. | 2015-01-29 | — | — | US | disclosed |
| CN-102812003-B | Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43) | EUROSCREEN SA | 2015-01-21 | — | — | CN | disclosed |
| US-20150010535-A1 | Methods of Identifying a Compound that Increases or Decreases the Interaction of Hn-33 with Synaptotagmin II | Singh, Bal Ram (US) | 2015-01-08 | — | — | US | disclosed |
| US-8927250-B2 | Polypeptides having alpha-amylase and granular starch hydrolyzing activity | DANISCO US INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140377841-A1 | Detergent Compositions Containing Bacillus Agaradhaerens Mannanase and Methods of Use Thereof | DANISCO US INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2280686-B1 | ALPHA-GLUCANASE AND ORAL CARE COMPOSITION CONTAINING THE SAME | DANISCO US INC (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2152726-B1 | ANALGESIC COMPOUNDS | FUNDAÇ O DE AMPARO PESQUISA DO ESTADO DE S O PAULO FAPESP (BR) | 2014-11-26 | — | — | EP | disclosed |
| US-20140342431-A1 | Variant Alpha-Amylases and Methods of Use, Thereof | DANISCO US INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8877479-B2 | Halomonas strain WDG195-related alpha-amylases, and methods of use, thereof | DANISCO US INC. (US) | 2014-11-04 | — | — | US | disclosed |
| CN-101848927-B | Analgesic compounds | Sao Paulo State Support Research Foundation (BR) | 2014-10-22 | — | — | CN | disclosed |
| US-20140287477-A1 | Variant Maltohexaose-Forming Alpha-Amylase Variants | DANISCO US INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140255443-A1 | Nucleic Acid And Amino Acid Sequences Relating To Streptococcus Pneumoniae For Diagnostics And Therapeutics | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2014-09-11 | — | — | US | disclosed |
| WO-2014130470-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-8815559-B2 | Amylase from nesterenkonia and methods of use, thereof | DANISCO US INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140234231-A1 | ALPHA-GLUCANASE AND ORAL CARE COMPOSITION CONTAINING THE SAME | DANISCO US INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8802388-B2 | Detergent compositions containing Bacillus agaradhaerens mannanase and methods of use thereof | DANISCO US INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140212510-A1 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER | US ARMY, SECRETARY OF THE ARMY | 2014-07-31 | — | — | US | disclosed |
| US-20140161808-A1 | ANTIBODIES THAT BIND NOVEL PCSK9 VARIANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| CN-101506360-B | Pullulanase variants with increased yield | DANISCO US INC GENENCOR DIV | 2014-06-11 | — | — | CN | disclosed |
| US-8748106-B2 | Methods of identifying a compound that increases or decreases the interaction of Hn-33 with synaptotagmin II | Singh, Bal Ram (US) | 2014-06-10 | — | — | US | disclosed |
| US-8741609-B2 | Detergent compositions containing Geobacillus stearothermophilus lipase and methods of use thereof | DANISCO US INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2406373-B1 | BACILLUS MEGATERIUM STRAIN DSM90-RELATED ALPHA-AMYLASES, AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2417254-B1 | HALOMONAS STRAIN WDG195-RELATED ALPHA-AMYLASES, AND METHODS OF USE, THEREOF | DANISCO US INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140135252-A1 | DETERGENT COMPOSITIONS CONTAINING GEOBACILLUS TEPIDAMANS MANNANASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2014-05-15 | — | — | US | disclosed |
| CN-101094918-B | Acid fungal proteases | GENENCOR INT | 2014-05-14 | — | — | CN | disclosed |
| US-8709386-B2 | Method of making and using an alpha-glucanase composition to reduce or remove biofilm | DANISCO US INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140113346-A1 | THERMOSTABLE CARBONIC ANHYDRASES AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140073548-A1 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SP. MANNANASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073030-A1 | DETERGENT COMPOSITIONS CONTAINING BACILLUS AGARADHAERENS MANNANASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2702152-A1 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SP. MANNANASE AND METHODS OF USE THEREOF | Danisco US Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8652488-B2 | Insulin B chain autoantigen composition | JOSLIN DIABETES CENTER, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8609107-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2013-12-17 | — | — | US | disclosed |
| EP-2671946-A1 | Polynucleotides encoding novel PCSK9 variants | Bristol-Myers Squibb Company (US) | 2013-12-11 | — | — | EP | disclosed |
| CN-101809146-B | Hydrocarbon-producing genes and methods of use thereof | LS9 INC | 2013-12-11 | — | — | CN | disclosed |
| EP-2664623-A1 | New antitumoral compounds | Pharma Mar, S.A.U. (ES) | 2013-11-20 | — | — | EP | disclosed |
| EP-2644187-A1 | Alpha-glucanase and oral care composition containing the same | Danisco US Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2641589-A1 | Alpha-glucanase and oral care composition containing the same | Danisco US Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8540984-B2 | Phytases with improved thermal stability | CORNELL RESEARCH FOUNDATION, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2639301-A2 | Polynucleotides encoding novel PCSK9 variants | Bristol-Myers Squibb Company (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130224756-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130224305-A1 | METHODS OF IDENTIFYING INSECT-TRPA1 MODULATORS | BRANDEIS UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013126622-A1 | METHODS FOR DISPLAYING POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20130196410-A1 | COMPOSITIONS AND METHODS FOR MODIFYING THE GLYCOSYLATION PATTERN OF A POLYPEPTIDE | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2012149333-A9 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SP. MANNANASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| US-20130177964-A1 | AMYLASE FROM NESTERENKONIA AND METHODS OF USE, THEREOF | DANISCO US INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130171150-A1 | FELINE PICORNA VIRUS AND USES THEREOF | CORNELL UNIVERSITY | 2013-07-04 | — | — | US | disclosed |
| EP-2609425-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | President and Fellows of Harvard College (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8455435-B2 | Combination of granulocyte-colony stimulating factor (G-CSF) and DPP-IV inhibitors like Vildagliptin or Sitagliptin | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8440795-B2 | Kunitz-type recombinant inhibitor | Coinfair-Consórcio De Indústrias Farmacêuticas (BR) | 2013-05-14 | — | — | US | disclosed |
| US-20130108612-A1 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2268806-B1 | Enzyme with microbial lysis activity from Trichoderma reesei | DANISCO US INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130078271-A1 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STREPTOCOCCUS PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2013-03-28 | — | — | US | disclosed |
| US-20130065820-A1 | SYNTHETIC MYOSTATIN PEPTIDE ANTAGONISTS | COVITA LIMITED (NZ) | 2013-03-14 | — | — | US | disclosed |
| WO-2013033310-A1 | MODULATORS OF REV-ERB | KAMENECKA THEODORE MARK (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130039934-A1 | TREATMENT OF IGE-MEDIATED DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| US-8354101-B2 | Pullulanase variants with increased productivity | DANISCO US INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354264-B2 | Polynucleotides encoding novel PCSK9 variants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| US-8349601-B2 | Trichoderma reesei glucoamylase and homologs thereof | DANISCO US INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120309063-A1 | DETERGENT COMPOSITIONS CONTAINING GEOBACILLUS STEAROTHERMOPHILUS LIPASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1918296-B1 | New antitumoral compounds | PHARMA MAR SAU (ES) | 2012-11-14 | — | — | EP | disclosed |
| US-8309068-B2 | Isolated polypeptides and methods of improving muscle strength | Myostin Therapeutics Pty Ltd. (AU) | 2012-11-13 | — | — | US | disclosed |
| WO-2012149333-A1 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SP. MANNANASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149047-A1 | MULTIMER GLYCOSYLATED NUCLEIC ACID BINDING PROTEIN CONJUGATES AND USES THEREOF | SEQUENOM, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276548-A1 | MULTIMER GLYCOSYLATED NUCLEIC ACID BINDING PROTEIN CONJUGATES AND USES THEREOF | SEQUENOM, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8298788-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2012-10-30 | — | — | US | disclosed |
| EP-2513053-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | Euroscreen S.A. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-8293776-B2 | Compositions and methods for treating inflammatory conditions of the bowel | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293249-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2012-10-23 | — | — | US | disclosed |
| US-8293884-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2012-10-23 | — | — | US | disclosed |
| US-20120264231-A1 | ASSAY FOR ORAI CALCIUM CHANNEL REGULATORS | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8288517-B2 | Acid fungal proteases | DANISCO US INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288519-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2012-10-16 | — | — | US | disclosed |
| US-20120258900-A1 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SUBTILIS LIPASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258507-A1 | DETERGENT COMPOSITIONS CONTAINING THERMOBIFIDA FUSCA LIPASE AND METHODS OF USE THEREOF | DANISCO US INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8278278-B2 | Cell proliferation reducing cancer specific PCNA peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120225469-A1 | ACID FUNGAL PROTEASES | DANISCO US INC. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2483300-A1 | SYNTHETIC MYOSTATIN PEPTIDE ANTAGONISTS | Covita Limited (NZ) | 2012-08-08 | — | — | EP | disclosed |
| EP-1984392-B1 | NOVEL CC-CHEMOKINE ANTAGONISTS | MERCK SERONO SA (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-20120195978-A1 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA (US) | 2012-08-02 | — | — | US | disclosed |
| US-8222371-B2 | vWFA and/or ANT—IG domain containing proteins | ARES TRADING S.A. (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20120171748-A1 | Halomonas Strain WDG195-Related Alpha-Amylases, And Methods Of Use, Thereof | DANISCO US INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172275-A1 | Bacillus Megaterium Strain DSM90-Related Alpha-Amylases, and Methods of Use, Thereof | DANISCO US INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8207116-B2 | Remedies for ischemia | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8192734-B2 | Compositions and methods for bone strengthening | CORNELL UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120135465-A1 | Endoglucanase For Reducing The Viscosity Of A Plant Materials Slurry | DANISCO US INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120129237-A1 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| EP-1492813-B1 | OX40R binding agents | MERCK SERONO SA (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-8173409-B2 | Acid fungal proteases | DANISCO US INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120058527-A1 | CAL A-RELATED ACYLTRANSFERASES AND METHODS OF USE, THEREOF | DANISCO US INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120052551-A1 | Polypeptides Having Alpha-Amylase And Granular Starch Hydrolyzing Activity | DANISCO US INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027358-A1 | OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-01 | — | — | WO | disclosed |
| US-8124730-B1 | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124729-B2 | Splice variants of human G-protein coupled receptor HGPRBMY29 (HGPRMBY29SV2) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120039915-A1 | GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120035350-A1 | POLYNUCLEOTIDE ENCODING A NOVEL HUMAN P2X7 SPLICE VARIANT, HBMYP2X7V | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-8110198-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120028318-A1 | FUNGAL CUTINASE FROM MAGNAPORTHE GRISEA | DANISCO US INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8105804-B2 | Polynucleotides encoding novel PCSK9 variants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20120010385-A1 | SPLICE VARIANTS OF HUMAN G-PROTEIN COUPLED RECEPTOR HGPRBMY29 (HGPRMBY29SV2) | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8093016-B2 | Use of an aspartic protease (NS24) signal sequence for heterologous protein expression | DANISCO US INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | disclosed |
| EP-1943272-B1 | NOVEL CXC-CHEMOKINE ANTAGONISTS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-20110281326-A1 | PULLULANASE VARIANTS WITH INCREASED PRODUCTIVITY | DANISCO US INC. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2382285-A2 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | LS9, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-8048412-B2 | Enzyme with microbial lysis activity from Trichoderma reesei | DANISCO US INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-1831362-B1 | ACID FUNGAL PROTEASES | GENENCOR INT (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011126882-A2 | THERAPEUTIC PEPTIDES AND THEIR DERIVATIVES AND THERAPEUTIC USES THEREOF | AMERICAN TYPE CULTURE COLLECTION (US) | 2011-10-13 | — | — | WO | disclosed |
| US-8034600-B2 | Polypeptides having alpha-amylase and granular starch hydrolyzing activity | DANISCO US INC. (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2011116214-A1 | METHODS OF IDENTIFYING INSECT-TRPA1 MODULATORS | BRANDEIS UNIVERSITY (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110223117-A1 | ALPHA-GLUCANASE AND ORAL CARE COMPOSITION CONTAINING THE SAME | DANISCO US INC. | 2011-09-15 | — | — | US | disclosed |
| WO-2011109600-A1 | COMPOSITIONS AND METHODS FOR MODIFYING THE GLYCOSYLATION PATTERN OF A POLYPEPTIDE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2363460-A2 | Acid fungal proteases | Genencor International, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-8003775-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2011-08-23 | — | — | US | disclosed |
| EP-1824970-B1 | TRICHODERMA REESEI GLUCOAMYLASE AND HOMOLOGS THEREOF | GENENCOR INT (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7985587-B2 | Methods of culturing dermal papilla cells | THE GENERAL HOSPITAL CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2338490-A2 | Combinations Useful for the Treatment of Neuronal Disorders | Probiodrug AG (DE) | 2011-06-29 | — | — | EP | disclosed |
| US-7968691-B2 | Hydrolase for use in textile treatment, food processing and fermentation of biofuels | DANISCO US INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2046830-B1 | CSF3R POLYPEPTIDES AND USES THEREOF | MERCK SERONO SA (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-1824881-B1 | TGR3-LIKE PROTEIN RECEPTOR | ARES TRADING SA (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | disclosed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | disclosed |
| WO-2011060018-A2 | COMPOSITIONS AND METHODS FOR USING PEPTIDES, MODIFIED PEPTIDES, PEPTIDOMIMETICS AND FIBRIN DERIVATIVES | IKARIA DEVELOPMENT SUBSIDIARY TWO LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060229-A1 | POROUS THIN FILMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| CN-102066416-A | Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RES & DEV GMBH | 2011-05-18 | — | — | CN | disclosed |
| US-20110086057-A1 | OX40R Binding Agents | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086408-A1 | Hemicellulase Enriched Compositions for Enhancing Hydrolysis of Biomass | DANISCO US INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2011040823-A1 | SYNTHETIC MYOSTATIN PEPTIDE ANTAGONISTS | COVITA LIMITED (NZ) | 2011-04-07 | — | — | WO | disclosed |
| US-7919299-B2 | Trichoderma reesei glucoamylase and homologs thereof | DANISCO US INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110076742-A1 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| US-20110076342-A1 | CANCER PEPTIDE THERAPEUTICS | US ARMY, SECRETARY OF THE ARMY | 2011-03-31 | — | — | US | disclosed |
| US-20110070626-A1 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2011-03-24 | — | — | US | disclosed |
| US-7906303-B2 | Use of Rhizopus amylases in granular starch hydrolysis | DANISCO US INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7893230-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7893238-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2011-02-22 | — | — | US | disclosed |
| US-20110033900-A1 | Trichoderma Reesei Glucoamylase and Homologs Thereof | GENENCOR INTERNATIONAL, INC. | 2011-02-10 | — | — | US | disclosed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20110027830-A1 | USE OF AN ASPARTIC PROTEASE (NS24) SIGNAL SEQUENCE FOR HETEROLOGOUS PROTEIN EXPRESSION | DANISCO US INC. | 2011-02-03 | — | — | US | disclosed |
| EP-2280025-A2 | New antitumoral compounds | Pharma Mar, S.A.U. (ES) | 2011-02-02 | — | — | EP | disclosed |
| EP-2280026-A2 | New antitumoral compounds | Pharma Mar, S.A.U. (ES) | 2011-02-02 | — | — | EP | disclosed |
| EP-2280027-A2 | New antitumoral compounds | Pharma Mar, S.A.U. (ES) | 2011-02-02 | — | — | EP | disclosed |
| US-20110020382-A1 | Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2011-01-27 | — | — | US | disclosed |
| US-7875437-B2 | Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7875439-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7875438-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2011-01-25 | — | — | US | disclosed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | disclosed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | disclosed |
| US-7871979-B2 | CSF3R polypeptides and uses thereof | MERCK SERONO SA (CH) | 2011-01-18 | — | — | US | disclosed |
| US-7867501-B2 | polypeptides derived from Streptococcus pneumoniae including surface or secreted proteins or parts thereof, that are useful as molecular targets for diagnostics, prophylaxis and treatment of bacterial infection; vaccines | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7858765-B2 | OX40R binding agents | MERCK SERONO SA (CH) | 2010-12-28 | — | — | US | disclosed |
| US-7846706-B2 | capable of lowering the level of LDL uptake in mammalian cells in which the polypeptide is recombinantly expressed; cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7834166-B2 | nucleic acids corresponding to entire coding sequences of S. pneumoniae proteins, including surface or secreted proteins or parts thereof; for diagnostics, prophylaxis and treatment of bacterial infection; vaccines | SANOFI PASTEUR LIMITED (CA) | 2010-11-16 | — | — | US | disclosed |
| US-7816490-B2 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | IMMUNE DISEASE INSTITUTE, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816325-B2 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | OSI PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7807384-B2 | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | BOSTON HEART FOUNDATION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100235934-A1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | LS9, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7795392-B2 | Organic anion transport proteins | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-7790428-B2 | Essential fungal polypeptide, CaYDR341c, and methods of use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790412-B2 | Membrane proteins; yeasts; baculovirus cells | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100196349-A1 | REELER DOMAIN CONTAINING PROTEIN | ARES TRADING S.A. (CH) | 2010-08-05 | — | — | US | disclosed |
| US-7767418-B2 | Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190208-A1 | ACID FUNGAL PROTEASES | DANISCO US INC. | 2010-07-29 | — | — | US | disclosed |
| US-7758852-B2 | OX40R binding agents | MERCK SERONO SA (CH) | 2010-07-20 | — | — | US | disclosed |
| WO-2010080188-A2 | EPITOPE TARGETED ANTHRAX VACCINE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010075483-A2 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | LS9, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100168443-A1 | Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2010-06-24 | — | — | US | disclosed |
| US-20100154293-A1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | AGAIN BIO APS (DK) | 2010-06-24 | — | — | US | disclosed |
| US-7741025-B2 | Method of diagnosing lung cancer using BGS42 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7740833-B2 | Therapeutic uses of chemokine variants | MERCK SERONO SA (CH) | 2010-06-22 | — | — | US | disclosed |
| US-20100136628-A1 | Novel OX40R Binding Agents | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-7723079-B2 | Given amino acid sequence; for use in animal feeds and detergents, starch conversion, ethanol production | GENENCOR INTERNATIONAL, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1183270-B1 | NOVEL ORGANIC ANION TRANSPORT PROTEINS | BRISTOL MYERS SQUIBB CO (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100119509-A1 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE DEVELOPMENT OF RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-7713699-B2 | Methods of diagnosing colon adenocarcinoma using mRNA encoding the human g-protein coupled receptor, HGPRBMY23 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7705134-B2 | immunoglobulins; fibronectins; drug screening | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705133-B2 | Antibodies which bind variants of the TRP channel family member, LTRPC3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | US | disclosed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043444-A2 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND/OR PREVENTION OF ISCHEMIA/REPERFUSION INJURY AND THE SEQUELS THEREOF | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | disclosed |
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20100068335-A1 | PHYTASES WITH IMPROVED THERMAL STABILITY | CORNELL RESEARCH FOUNDATION, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1543023-B1 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | PROSIDION LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-2160460-A2 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | LS9, Inc. (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7670802-B2 | CXC-chemokine antagonists isolated from Rhipicephalus sanguineus | MERCK SERONO SA (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7670785-B2 | Drug screening for a compound that modulates the NF kappa B activity of a guanylate binding protein associated with rheumatoid arthritis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100048467-A1 | Cystine-Knot Fold Cytokine | ARES TRADING S.A. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1263954-B1 | LOW DENSITY LIPROTEIN BINDING PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING ATHEROSCLEROSIS | BOSTON HEART FOUNDATION INC (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2152726-A1 | ANALGESIC COMPOUNDS | Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (BR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2010017312-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE BOWEL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035852-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE BOWEL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100028327-A1 | NOVEL LOW DENSITY LIPOPROTEIN BINDING PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING ATHEROSCLEROSIS | BOSTON HEART FOUNDATION, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100028302-A1 | Use of IGFBP-2 in Senescence Diseases and for the Maintenance of Organ Functions | LUDWIG-MAXIMILIANS- UNIVERSITÄT MÜNCHEN (DE) | 2010-02-04 | — | — | US | disclosed |
| US-7655684-B2 | 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease | PROBIODRUG AG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100003736-A1 | capable of lowering the level of LDL uptake in mammalian cells in which the polypeptide is recombinantly expressed; cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
| US-20100004167-A1 | CSF3R POLYPEPTIDES AND USES THEREOF | LABORATOIRES SERONO SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090324590-A1 | MYOSTATIN ANTAGONISTS | MDX BIOTECH PTY LIMITED (AU) | 2009-12-31 | — | — | US | disclosed |
| EP-2134843-A1 | KUNITZ-TYPE RECOMBINANT INHIBITOR | Unico Quemica Farmaceutica Nacional S/A (BR) | 2009-12-23 | — | — | EP | disclosed |
| US-7635576-B2 | CC-chemokine binding tick proteins | MERCK SERONO SA (CH) | 2009-12-22 | — | — | US | disclosed |
| US-7635758-B2 | Antibodies directed to G-protein coupled receptor HGPRBMY29sv1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090304698-A1 | MODULATION OF OVULATION | AGRESEARCH LIMITED (NZ) | 2009-12-10 | — | — | US | disclosed |
| US-20090305373-A1 | Trichoderma reesei glucoamylase and homologs thereof | DUNN-COLEMAN NIGEL | 2009-12-10 | — | — | US | disclosed |
| US-7629451-B2 | Acid fungal proteases | GENENCOR INTERNATIONAL, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090297470-A1 | REMEDIES FOR ISCHEMIA | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN | 2009-12-03 | — | — | US | disclosed |
| US-7625939-B2 | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | PROBIODRUG AG (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7626000-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2009-12-01 | — | — | US | disclosed |
| US-20090286730-A1 | REMEDIES FOR ISCHEMIA | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN | 2009-11-19 | — | — | US | disclosed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | disclosed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | disclosed |
| US-20090285838-A1 | USE OF SOLUBLE CD164 IN INFLAMMATION AND AUTOIMMUNE DISORDERS | LABORATOIRES SERONO SA (CH) | 2009-11-19 | — | — | US | disclosed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | disclosed |
| US-7611867-B2 | CC-chemokine binding tick proteins | MERCK SERONO SA (CH) | 2009-11-03 | — | — | US | disclosed |
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608450-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090253191-A1 | USE OF RHIZOPUS AMYLASES IN GRANULAR STARCH HYDROLYSIS | DANISCO US INC. | 2009-10-08 | — | — | US | disclosed |
| US-7598348-B2 | Adiponectin receptor variant, AdipoR2v2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090232788-A1 | Enzyme With Microbial Lysis Activity From Trichoderma Reesei | DANISCO US INC., GENENCOR DIVISION (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1817430-B1 | MEANS AND METHODS FOR DETECTING METHYLATED DNA | UNIV REGENSBURG KLINIKUM (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-7588920-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1802653-B1 | MAM DOMAIN CONTAINING PROTEIN | ARES TRADING SA (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-1819722-A4 | MODULATION OF OVULATION | AGRES LTD (NZ) | 2009-09-09 | — | — | EP | disclosed |
| US-20090221030-A1 | SIGNAL SEQUENCES AND CO-EXPRESSED CHAPERONES FOR IMPROVING PROTEIN PRODUCTION IN A HOST CELL | DANISCO US INC. | 2009-09-03 | — | — | US | disclosed |
| US-7582731-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2009-09-01 | — | — | US | disclosed |
| US-20090215672-A1 | Cys-Rich, Cell Surface Glycoproteins | ARES TRADING S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090215149-A1 | Membrane proteins; recombinant vectors, cells | GENOME THERAPEUTIC CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090214548-A1 | TGR3-Like Protein Receptor | ARES TRADING S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-7572618-B2 | Polynucleotides encoding novel PCSK9 variants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7566776-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566769-B2 | Tumor necrosis factor related ligand | BIOGEN IDEC MA INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090186422-A1 | SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES | THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC., A MASSACHUSETTS CORPORATION | 2009-07-23 | — | — | US | disclosed |
| EP-1697404-B1 | CC-CHEMOKINE BINDING TICK PROTEINS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-7553483-B2 | Chemokine mutants acting as chemokine antagonists | MERCK SERONO SA (CH) | 2009-06-30 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090155237-A1 | COMPOSITIONS AND METHODS FOR BONE STRENGTHENING | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090148890-A1 | Membrane proteins; yeasts; baculovirus cells | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2009-06-11 | — | — | US | disclosed |
| US-7541434-B2 | Polypeptide for a TRP channel family member, TRP-PLIK2, and splice variants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541435-B2 | Antagonists of cxcr3-binding cxc chemokines | MERCK SERONO SA (CH) | 2009-06-02 | — | — | US | disclosed |
| US-20090130659-A1 | KITS AND METHODS FOR DETECTING METHYLATED DNA | KLINIKUM DER UNIVERSITAET REGENSBURG | 2009-05-21 | — | — | US | disclosed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7531310-B2 | Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531625-B2 | β netrin and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| EP-2053403-A2 | Affinity fishing for ligands and proteins receptors | Novo Nordisk A/S (DK) | 2009-04-29 | — | — | EP | disclosed |
| US-20090104197-A1 | vWFA and/or ANT_IG Domain Containing Proteins | ARES TRADING S.A. (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090104681-A1 | Polypeptides Having Alpha-Amylase and Granular Starch Hydrolyzing Activity | DANISCO US INC. | 2009-04-23 | — | — | US | disclosed |
| US-7517684-B2 | Nucleic acid and amino acid sequences relating to Pseudomonas aeruginosa for diagnostics and therapeutics | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090088385-A1 | immunoglobulins; fibronectins; drug screening | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-02 | — | — | US | disclosed |
| EP-1828234-B1 | CC-CHEMOKINE ANTAGONISTS | SERONO LAB (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20090074806-A1 | nucleic acids corresponding to entire coding sequences of S. pneumoniae proteins, including surface or secreted proteins or parts thereof; for diagnostics, prophylaxis and treatment of bacterial infection; vaccines | DOUCETTE-STAMM LYNN | 2009-03-19 | — | — | US | disclosed |
| US-7504481-B2 | TRP channel family member, LTRPC3 polypeptides | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504490-B1 | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090068173-A1 | NOVEL CC-CHEMOKINE ANTAGONISTS | LABORATOIRES SERONO S.A. (CH) | 2009-03-12 | — | — | US | disclosed |
| US-20090061483-A1 | ACID FUNGAL PROTEASES | DANISCO US INC. | 2009-03-05 | — | — | US | disclosed |
| US-7494685-B2 | Trichoderma reesei glucoamylase and homologs thereof | GENENCOR INTERNATIONAL, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20090042786-A1 | Kunitz-type recombinant inhibitor | COINFAR - CONSORCIO DE INDUSTRIAS FARMACEUTICAS (BR) | 2009-02-12 | — | — | US | disclosed |
| EP-1458756-B1 | CHEMOKINE MUTANTS ACTING AS CHEMOKINE ANTAGONISTS | SERONO LAB (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20090022657-A1 | Novel CXCL8 antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2009-01-22 | — | — | US | disclosed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090017054-A1 | nucleic acids corresponding to entire coding sequences of S. pneumoniae proteins, including surface or secreted proteins or parts thereof; for diagnostics, prophylaxis and treatment of bacterial infection; vaccines | DOUCETTE-STAMM LYNN | 2009-01-15 | — | — | US | disclosed |
| US-7476381-B2 | Methods of reducing serum alanine transferase levels in a subject with hepatitis | LABORATOIRES SERONO SA (CH) | 2009-01-13 | — | — | US | disclosed |
| US-20090004184-A1 | Polynucleotides and polypeptides associated with the development of rheumatoid arthritis | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-2007416-A2 | REMEDIES FOR ISCHEMIA | Ludwig-Maximilians-Universität München (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080318257-A1 | Polynucelotides encoding novel variants of the TRP channel family member, LTRPC3 | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-25 | — | — | US | disclosed |
| US-7465568-B2 | Essential fungal polynucleotides, polypeptides, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080305524-A1 | Molecular Glue | UNIVERSITAT REGENSBURG (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080299619-A1 | Given amino acid sequence; for use in animal feeds and detergents, starch conversion, ethanol production | GENENCOR INTERNATIONAL, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008147781-A2 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | LS9, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-7459532-B2 | Variants of the TRP channel family member, LTRPC3G | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080293618-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1673388-B1 | CXCL8 ANTAGONISTS | SERONO LAB (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1588173-B1 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | NOVO NORDISK AS (DK) | 2008-11-26 | — | — | EP | disclosed |
| US-7456256-B2 | BGS 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080286261-A1 | Methods of modulating hair growth | THE GENERAL HOSPITAL CORPORATION | 2008-11-20 | — | — | US | disclosed |
| US-20080287363-A1 | Novel Cc-Chemokine Antagonists | LABORATOIRES SERONO SA (CH) | 2008-11-20 | — | — | US | disclosed |
| WO-2008131508-A1 | ANALGESIC COMPOUNDS | FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP (BR) | 2008-11-06 | — | — | WO | disclosed |
| US-20080274505-A1 | Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| EP-1465996-B1 | RAF/RAS BINDING COMPOUNDS | SERONO LAB (CH) | 2008-11-05 | — | — | EP | disclosed |
| US-7442523-B2 | Nucleotide sequences coding bacterial surface protein for use in development of vaccines and prevention of infection | SANOFI PASTEUR LIMITED (CA) | 2008-10-28 | — | — | US | disclosed |
| US-7442532-B2 | Essential fungal CaYLR100w polypeptides, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080260743-A1 | Means and Methods for Detecting Methylated Dna | KLINIKUM DER UNIVERSITÄT REGENSBURG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080254035-A1 | Lipocalin Protein | ARES TRADING S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-7435808-B2 | Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-14 | — | — | US | disclosed |
| US-7429476-B2 | Acid fungal proteases | GENENCOR INTERNATIONAL, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1971614-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | Probiodrug AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| US-20080226627-A1 | Using clostridium botulinum neurotoxin complex (Hn-33) protein as diagnostic tool in identifying modulators for treatment and prevention of clostridial poisoning; antitumor agents | US ARMY, SECRETARY OF THE ARMY | 2008-09-18 | — | — | US | disclosed |
| WO-2008109976-A1 | KUNITZ-TYPE RECOMBINANT INHIBITOR | UNIÃO QUÍMICA FARMACÊUTICA NACIONAL S/A (BR) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227711-A1 | Cxc-Chemokine Antagonists | LABORATOIRES SERONO SA (CH) | 2008-09-18 | — | — | US | disclosed |
| US-20080226640-A1 | C1q Related Protein | ARES TRADING S.A. (CH) | 2008-09-18 | — | — | US | disclosed |
| US-7425324-B2 | Monocyte chemoattractant protein(MCP), mutants whose mucopolysaccharide binding site is eliminated by replacements, used to inhibit the migration and activation of leukocytes expressing their receptors; prevention of cancer, inflammatory, autoimmune and vascular diseases | LABORATOIRES SERONO SA (CH) | 2008-09-16 | — | — | US | disclosed |
| US-20080221305-A1 | Polynucleotides encoding novel adiponectin receptor variants | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080213286-A1 | Mam Domain Containing Protein | ARES TRADING S.A. (CH) | 2008-09-04 | — | — | US | disclosed |
| US-20080213918-A1 | Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-7417121-B2 | Human G-protein coupled receptor, HGPRBMY39 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7416862-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| US-7413879-B2 | Using amylase to hydrolyze starch for use in fermentation of ethanol | GENENCOR INTERNATIONAL, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7413887-B2 | DNA sequence encoding enzyme obtained from filamentous fungi; fermenting cell transformed with polypeptide | GENECOR INTERNATIONAL, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080194004-A1 | Point mutations; antibodies; fusion proteins | DOUCETTE-STAMM LYNN | 2008-08-14 | — | — | US | disclosed |
| US-20080194505-A1 | Point mutations; antibodies; fusion proteins | DOUCETTE-STAMM LYNN | 2008-08-14 | — | — | US | disclosed |
| US-20080196113-A1 | Lipocalin Protein | ARES TRADING S.A. (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080187965-A1 | Using transgenic escherichia as bioreactor for producing immunoglobulins specific to streptococcal capsular protein for use in treatment and prevention of bacterial infection | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2008-08-07 | — | — | US | disclosed |
| US-7404958-B2 | Administering polypeptide which elicits an immune response | SANOFI PASTEUR LIMITED (CA) | 2008-07-29 | — | — | US | disclosed |
| US-7405291-B2 | A nucleic acid encoding a S. pneumoniae surface protein having at least 95% identity to SEQ ID NO: 5243;.diagnosis and therapy of infections; antibodies against the polypeptides; vacines; genetic engineering;screening bactericides; antibodies as probes to detect infection by S. pneumoniae | SANOFI PASTEUR LIMITED (CA) | 2008-07-29 | — | — | US | disclosed |
| US-20080177026-A1 | Bacterial polypeptide for use in diagnosis, prevetntion and treatment of microorganismal infection; immunotherapy | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2008-07-24 | — | — | US | disclosed |
| US-20080175854-A1 | Point mutations; antibodies; fusion proteins | GENOME THERAPEUTICS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7402395-B2 | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | BOSTON HEART FOUNDATION, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7396532-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2008-07-08 | — | — | US | disclosed |
| US-7393660-B2 | CC-chemokine binding tick proteins | LABORATOIRES SERONO SA (CH) | 2008-07-01 | — | — | US | disclosed |
| US-20080153892-A1 | Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080152642-A1 | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof | THE GENERAL HOSPITAL CORPORATION, A MASSACHUSETTS CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-7390493-B2 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2008-06-24 | — | — | US | disclosed |
| US-7390634-B2 | β-netrin and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7388090-B2 | molecular targets for diagnostics, prophylaxis and treatment of bacterial infection; cell comprising the recombinant expression vector | SANOFI PASTEUR LIMITED (CA) | 2008-06-17 | — | — | US | disclosed |
| US-7385047-B1 | Isolated polypeptide and nucleic acid sequences derived from S. pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides; bactericides; vaccines; antibodies; target screening | SANOFI PASTEUR LIMITED (CA) | 2008-06-10 | — | — | US | disclosed |
| US-20080131963-A1 | Expression vector comprising nucleotide sequences coding streptococcal surface protein for use in detection, prevention and treatment of microorganismal infection | AVENTIS PASTEUR LTD (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080131964-A1 | Expression vector comprising nucleotide sequences coding streptococcal surface protein for use in detection, prevention and treatment of microorganismal infection | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2008-06-05 | — | — | US | disclosed |
| US-7381816-B2 | Recombinant expression vector comprising nucleic acid linked to transcription regulatory element; immunogen; prophylaxis and treatment of bacterial infections | SANOFI PASTEUR LIMITED (CA) | 2008-06-03 | — | — | US | disclosed |
| US-7381814-B1 | Recombinant expression vector comprising nucleic acid linked to transcription regulatory element; prophylaxis and treatment of bacterial infections | SANOFI PASTEUR LIMTED (CA) | 2008-06-03 | — | — | US | disclosed |
| US-7381815-B2 | Recombinant expression vector comprising nucleic acid linked to transcription regulatory element; prophylaxis and treatment of bacterial infections | SANOFI PARKER LIMITED (CA) | 2008-06-03 | — | — | US | disclosed |
| US-20080124794-A1 | Expression vector comprising nucleotide sequences coding streptococcal surface protein for use in detection, prevention and treatment of microorganismal infection | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2008-05-29 | — | — | US | disclosed |
| US-7378514-B2 | molecular targets for diagnostics, prophylaxis and treatment of bacterial infection; | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7378258-B2 | Antibodies; transcription regulators; bacterial infections; vectors; host cells | SANOFI PASTEUR LIMITED (CA) | 2008-05-27 | — | — | US | disclosed |
| US-20080118953-A1 | Isolated polypeptide and nucleic acid sequences derived from S. pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides; bactericides; vaccines; antibodies; target screening | DOUCETTE-STAMM LYNN | 2008-05-22 | — | — | US | disclosed |
| US-20080118971-A1 | Nucleotide sequences coding microorganismal polypeptides for use in diagnosis, prevention and treatment of bacterial infection | DOUCETTE-STAMM LYNN | 2008-05-22 | — | — | US | disclosed |
| US-20080118952-A1 | Polynucelotides encoding novel variants of the TRP channel family member, LTRPC3 | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| WO-2006059913-A9 | MODULATION OF OVULATION | AGRES LTD (NZ) | 2008-05-22 | — | — | WO | disclosed |
| US-20080113430-A1 | Nucleotide sequences coding bacterial surface protein for use in development of vaccines and prevention of infection | AVENTIS PASTEUR LTD (CA) | 2008-05-15 | — | — | US | disclosed |
| US-20080113429-A1 | Nucleotide sequences coding bacterial surface protein for use in development of vaccines and prevention of infection | AVENTIS PASTEUR LTD (CA) | 2008-05-15 | — | — | US | disclosed |
| US-7371871-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2008-05-13 | — | — | US | disclosed |
| US-7371822-B2 | Human G-protein coupled receptor variant of HM74, HGPRBMY74 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20080108126-A1 | PULLULANASE VARIANTS WITH INCREASED PRODUCTIVITY | DANISCO US INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1918296-A2 | New antitumoral compounds | Pharma Mar, S.A.U. (ES) | 2008-05-07 | — | — | EP | disclosed |
| EP-1434792-B1 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROSIDION LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| EP-1575608-B1 | USE OF CC-CHEMOKINE CCL5/RANTES MUTANTS AGAINST LIVER DISEASES | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1664093-B1 | Antitumoral compounds based on Kahalalide F | PHARMA MAR SAU (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7358074-B2 | Human phosphatase RET31, and variants thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080076153-A1 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2008-03-27 | — | — | US | disclosed |
| US-7348149-B2 | Methods of diagnosing Parkinson's disease by measuring expression level of RNA encoding human protein HLLRCR-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7344860-B2 | Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345148-B2 | Human G-protein coupled receptor, HGPRBMY29sv1 polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344882-B2 | Polynucleotides encoding variants of the TRP channel family member, LTRPC3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080064094-A1 | Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-03-13 | — | — | US | disclosed |
| US-20080064083-A1 | Expression vector comprising bacterial nucleotide sequences for use in diagnosis, prevention and treatment of microorganismal infection | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2008-03-13 | — | — | US | disclosed |
| US-7338786-B2 | Reagents for diagnosis of bacterial infection, components of effective antibacterial vaccines, and/or as targets for antibacterial drugs, including anti-S. pneumoniae drugs | SANOFI PASTEUR LIMITED (CA) | 2008-03-04 | — | — | US | disclosed |
| US-7339032-B2 | Human relaxin receptor HGPRBMY5v1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080050369-A1 | Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-02-28 | — | — | US | disclosed |
| US-7335493-B2 | nucleic acids capable of binding mRNA from Streptococcus. pneumoniae proteins to block protein translation; a cell containing the recombinant expression vector of such nucleic acid operably linked to a transcription regulatory element | SANOFI PASTEUR LIMITED (CA) | 2008-02-26 | — | — | US | disclosed |
| US-7335494-B2 | nucleic acids capable of binding mRNA from Streptococcus. pneumoniae proteins to block protein translation; a cell containing the recombinant expression vector of such nucleic acid operably linked to a transcription regulatory element | SANOFI PASTEUR LIMITED (CA) | 2008-02-26 | — | — | US | disclosed |
| US-20080038255-A1 | Splice Variant of Unc5h2 | APLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-02-14 | — | — | US | disclosed |
| EP-1885815-A1 | MOLECULAR GLUE | Universität Regensburg (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20080032339-A1 | Using transgenic escherichia as bioreactor for producing immunoglobulins specific to streptococcal capsular protein for use in treatment and prevention of bacterial infection | DOUCETTE-STAMM LYNN | 2008-02-07 | — | — | US | disclosed |
| US-20080031889-A1 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| US-7326544-B2 | Reagents for diagnosis of bacterial infection, components of antibacterial vaccines, and/or as targets for antibacterial drugs | SANOFI PASTEUR LIMITED (CA) | 2008-02-05 | — | — | US | disclosed |
| US-7326781-B2 | Polynucleotides encoding the human citron kinase polypeptide, BMSNKC—0020/0021 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20080026363-A1 | ACETYL COA CARBOXYLASE 2 SEQUENCES AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026401-A1 | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42 | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| CN-101115767-A | vWFA and/or ANT_IG domain containing proteins | ARES TRADING SA (CH) | 2008-01-30 | — | — | CN | disclosed |
| US-20080019958-A1 | POLYNUCLEOTIDE ENCODING A NOVEL ACYL COENZYME A, MONOACYLGLYCEROL ACYLTRANSFERASE-3 (MGAT3), AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-24 | — | — | US | disclosed |
| US-20080020442-A1 | Reagents for diagnosis of bacterial infection, components of antibacterial vaccines, and/or as targets for antibacterial drugs | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2008-01-24 | — | — | US | disclosed |
| US-20080014593-A1 | Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080008697-A1 | Atherosclerosis; coronary heart disease; encodes a polypeptide that is capable of lowering the level of LDL uptake in mammalian cells | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009068-A1 | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction | Georges, Elias (CA) | 2008-01-10 | — | — | US | disclosed |
| US-20080009035-A1 | Culturing a host cell that includes a specific recombinant expression vector to produce reagents for diagnosis of bacterial infection, components of antibacterial vaccines, and/or as targets for antibacterial drugs | DOUCETTE-STAMM LYNN | 2008-01-10 | — | — | US | disclosed |
| US-7312086-B2 | Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293426-A1 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| US-7309779-B2 | Antibodies directed to the testis-specific tubulin tyrosine-ligase-like protein, BGS42 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-18 | — | — | US | disclosed |
| EP-0723555-B1 | CHIMERIC PROTEINS WHICH BLOCK COMPLEMENT ACTIVATION | MILLENNIUM PHARM INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070280958-A1 | Therapeutic Uses Of Chemokine Variants | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-12-06 | — | — | US | disclosed |
| EP-1862555-A1 | Means and methods for diagnosing cancer or a corresponding predisposition | Klinikum der Universität Regensburg (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-7304141-B2 | Human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| EP-0871463-B2 | REGULATION OF EATING BEHAVIOR | JOSLIN DIABETES CT (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070265218-A1 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2007-11-15 | — | — | US | disclosed |
| US-7288632-B2 | Dropsophila tumor necrosis factor class molecule (“DmTNFv2”) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2007118680-A2 | REMEDIES FOR ISCHEMIA | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-7285633-B2 | Metalloprotease highly expressed in the testis, MMP-29 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070243585-A1 | Using expression vector comprising bacterial nucleotide sequences to prepare polypeptides for use in diagnosis, prevention and treatment of microorganismal infection | DOUCETTE-STAMM LYNN | 2007-10-18 | — | — | US | disclosed |
| US-20070243586-A1 | Novel organic anion transport proteins | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-18 | — | — | US | disclosed |
| US-20070243207-A1 | Using streptococcal polypeptide as tool to generate immunoglobulin and vaccine compounds which diagnosis, treat and prevent microorganismal infection | DOUCETTE-STAMM LYNN | 2007-10-18 | — | — | US | disclosed |
| US-7279550-B2 | Irreversible cysteine protease inhibitors of legumain | PROBIODRUG AG (DE) | 2007-10-09 | — | — | US | disclosed |
| CN-100340287-C | Method for preventing UVB-induced skin damage | GEN HOSPITAL CORP (US) | 2007-10-03 | — | — | CN | disclosed |
| US-7276354-B2 | Polynucleotides encoding a novel human G-protein coupled receptor splice variant, HGPRBMY29SV2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070224125-A1 | Cc-Chemokine Binding Tick Proteins | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-09-27 | — | — | US | disclosed |
| US-7273929-B2 | B1k chain of laminin and methods of use | THE GENERAL HOSPITAL CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273706-B2 | Method of diagnosing testicular tumors using polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7268155-B2 | Photosensitizer conjugates for pathogen targeting | THE GENERAL HOSPITAL CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070207976-A1 | Nucleic acids and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-09-06 | — | — | US | disclosed |
| US-20070207946-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | POSPISILIK ANDREW J | 2007-09-06 | — | — | US | disclosed |
| EP-1824999-A1 | KITS AND METHODS FOR DETECTING METHYLATED DNA | Klinikum der Universität Regensburg (DE) | 2007-08-29 | — | — | EP | disclosed |
| EP-1824846-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-20070196897-A1 | POLYNUCLEOTIDES ENCODING A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR SPLICE VARIANT, HGPRBMY29SV2 | FEDER JOHN N | 2007-08-23 | — | — | US | disclosed |
| EP-1819726-A1 | MODULATION OF OVULATION | Agresearch Limited (NZ) | 2007-08-22 | — | — | EP | disclosed |
| EP-1819722-A1 | MODULATION OF OVULATION | Agresearch Limited (NZ) | 2007-08-22 | — | — | EP | disclosed |
| US-7259002-B2 | Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070190613-A1 | Novel essential fungal polynucleotides, polypeptides, and methods of use | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-16 | — | — | US | disclosed |
| EP-1817430-A2 | MEANS AND METHODS FOR DETECTING METHYLATED DNA | Klinikum der Universität Regensburg (DE) | 2007-08-15 | — | — | EP | disclosed |
| US-7256267-B2 | Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1267616-B1 | METHODS OF INCREASING HAIR GROWTH BY WNT POLYPEPTIDE | GEN HOSPITAL CORP (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070178088-A1 | Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunoglobulin folds, BGS2, 3 and 4 and variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-20070172881-A1 | Novel essential fungal polynucleotides, polypeptides, and methods of use | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-26 | — | — | US | disclosed |
| US-20070172880-A1 | Polynucleotide encoding a novel TRP channel family member, TRP-PLIK2, and splice variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-26 | — | — | US | disclosed |
| US-7244410-B2 | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | BOSTON HEART FOUNDATION, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244573-B2 | Polynucleotides and polypeptides associated with the development of rheumatoid arthritis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7235375-B2 | Organic anion transport proteins | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070141590-A1 | Sequences encoding Kidney Injury-related Molecules (KIM) which are upregulated in renal tissue after injury to the kidney and antibodies against KIMs; use in diagnosis and treatment of renal cancer | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-06-21 | — | — | US | disclosed |
| CN-1321682-C | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2007-06-20 | — | — | CN | disclosed |
| US-7226791-B2 | Polynucleotides encoding novel guanylate binding proteins (GBP's) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7223558-B2 | Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223557-B2 | Polynucleotide encoding a TRP channel family member, TRP-PLIK2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070117965-A1 | Streptococcal polypeptide specific immunoglobulin for use in diagnosis, prevention and treatment of microoganismal infection; genetic vaccines | DOUCETTE-STAMM LYNN | 2007-05-24 | — | — | US | disclosed |
| US-20070117743-A1 | New antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2007-05-24 | — | — | US | disclosed |
| WO-2007054577-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PROBIODRUG AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099861-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-05-03 | — | — | US | disclosed |
| US-7211423-B2 | Acetyl CoA carboxylase 2 sequences and methods | BRISTOL-MYERS SQUIBB CO. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070093647-A1 | Membrane proteins; immunology | DOUCETTE-STAMM LYNN | 2007-04-26 | — | — | US | disclosed |
| US-20070093648-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-04-26 | — | — | US | disclosed |
| US-20070092946-A1 | Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-04-26 | — | — | US | disclosed |
| US-20070088150-A1 | bacterial surface protein for use in development of vaccines and prevention of bacterial infections | DOUCETTE-STAMM LYNN | 2007-04-19 | — | — | US | disclosed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070082005-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-04-12 | — | — | US | disclosed |
| US-20070083038-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-04-12 | — | — | US | disclosed |
| EP-1515990-B1 | ANTAGONISTS OF CXCR3-BINDING CXC CHEMOKINES | APPLIED RESEARCH SYSTEMS (AN) | 2007-04-11 | — | — | EP | disclosed |
| US-7198912-B2 | Polynucleotides encoding a human G-protein coupled receptor, HGPRBMY39 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-7196170-B2 | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070067858-A1 | Novel il-8-like polypeptides | LABORATOIRES SERONO SA (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070059801-A1 | Recombinant expression vector comprising nucleic acid linked to transcription regulatory element; prophylaxis and treatment of bacterial infections | DOUCETTE-STAMM LYNN | 2007-03-15 | — | — | US | disclosed |
| US-20070059802-A1 | Polypeptides and nucleic acids derived from S. pneumoniae that are useful as reagents for diagnosis of bacterial infection, components of effective antibacterial vaccines, and/or as targets for antibacterial drugs; genetic enginnering; nucleotide sequences; binding mRNA to block protein translation | DOUCETTE-STAMM LYNN | 2007-03-15 | — | — | US | disclosed |
| US-7189539-B2 | Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189829-B2 | Baboon TAFI polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070053936-A1 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | DOUCETTE-STAMM LYNN A | 2007-03-08 | — | — | US | disclosed |
| US-7186564-B2 | Polynucleotides encoding novel cysteine proteases of the calpain superfamily, CAN-12v1 and CAN-12v2. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7183083-B2 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | WYETH (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183379-B2 | Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070042403-A1 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | CENTER FOR BLOOD RESEARCH, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070042391-A1 | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics | DOUCETTE-STAMM LYNN A | 2007-02-22 | — | — | US | disclosed |
| US-20070037163-A1 | Expression vector comprising nucleotide sequences coding microorganismal polypeptide for use in generating agents for prevention and treatment of infection | GENOME THERAPEUTICS CORPORATION (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037766-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-02-15 | — | — | US | disclosed |
| US-7176035-B2 | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction | Georges, Elias (CA) | 2007-02-13 | — | — | US | disclosed |
| US-7175842-B2 | Methods of modulating hair growth | THE GENERAL HOSPITAL CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070031852-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | AVENTIS PASTEUR LTD (CA) | 2007-02-08 | — | — | US | disclosed |
| US-20070031888-A1 | Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1 | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
| US-20070027309-A1 | Nucleic acid and amino acid sequences relating to Candida albicans for diagnostics and therapeutics | WEINSTOCK KEITH G | 2007-02-01 | — | — | US | disclosed |
| US-20070026448-A1 | Polynucleotide encoding a novel human G-protein coupled receptor, HBPRBMY39 | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-01 | — | — | US | disclosed |
| US-20070021374-A1 | polypeptides derived from Streptococcus pneumoniae including surface or secreted proteins or parts thereof, that are useful as molecular targets for diagnostics, prophylaxis and treatment of bacterial infection; vaccines | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070021373-A1 | Administering polypeptide which elicits an immune response | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070021371-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070020624-A1 | Nucleic acid and amino acid sequences relating to Pseudomonas aeruginosa for diagnostics and therapeutics | GENOME THERAPEUTICS CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
| US-20070021372-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070021370-A1 | Administering polypeptide which elicits immune response; antibodies useful as probes for detection; vaccines | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070021369-A1 | Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070021601-A1 | nucleic acids corresponding to entire coding sequences of S. pneumoniae proteins, including surface or secreted proteins or parts thereof; for diagnostics, prophylaxis and treatment of bacterial infection; vaccines | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070021600-A1 | Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics | GENOME THERAPEUTICS CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021368-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | DOUCETTE-STAMM LYNN | 2007-01-25 | — | — | US | disclosed |
| US-20070015256-A1 | molecular targets for diagnostics, prophylaxis and treatment of bacterial infection; cell comprising the recombinant expression vector | DOUCETTE-STAMM LYNN | 2007-01-18 | — | — | US | disclosed |
| US-20070015255-A1 | Recombinant expression vector comprising nucleic acid linked to transcription regulatory element; immunogen; prophylaxis and treatment of bacterial infections | DOUCETTE-STAMM LYNN | 2007-01-18 | — | — | US | disclosed |
| US-20070015266-A1 | Using amylase to hydrolyze starch for use in fermentation of ethanol | GENENCOR INTERNATIONAL, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070016967-A1 | Novel IFNgamma-like polypeptides | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015906-A1 | Novel essential fungal polynucleotides, polypeptides, and methods of use | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070009902-A1 | Nucleotide sequences coding bacterial surface protein for use in development of vaccines and prevention of infection | AVENTIS PASTEUR LTD. (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070009901-A1 | molecular targets for diagnostics, prophylaxis and treatment of bacterial infection; | AVENTIS PASTEUR LTD (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070009905-A1 | nucleic acids capable of binding mRNA from Streptococcus. pneumoniae proteins to block protein translation; a cell containing the recombinant expression vector of such nucleic acid operably linked to a transcription regulatory element | AVENTIS PASTEUR LTD. (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070010665-A1 | Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics | BRETON GARY L | 2007-01-11 | — | — | US | disclosed |
| US-20070009906-A1 | Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics | AVENTIS PASTEUR LTD (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070009964-A1 | Ox40r binding agents | APPLIED RESEARCH SYSTMES ARD HOLDING N.V. (NL) | 2007-01-11 | — | — | US | disclosed |
| US-20070009904-A1 | Reagents for diagnosis of bacterial infection, components of effective antibacterial vaccines, and/or as targets for antibacterial drugs, including anti-S. pneumoniae drugs | AVENTIS PASTEUR LTD (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070009903-A1 | Reagents for diagnosis of bacterial infection, components of antibacterial vaccines, and/or as targets for antibacterial drugs | AVENTIS PASTEUR LTD (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070009900-A1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | AVENTIS PASTEUR LTD (CA) | 2007-01-11 | — | — | US | disclosed |
| US-20070004906-A1 | Monocyte chemoattractant protein(MCP), mutants whose mucopolysaccharide binding site is eliminated by replacements, used to inhibit the migration and activation of leukocytes expressing their receptors; prevention of cancer, inflammatory, autoimmune and vascular diseases | NATIONAL INSTITUTES OF HEALTH | 2007-01-04 | — | — | US | disclosed |
| US-20070004018-A1 | Trichoderma reesei glucoamylase and homologs thereof | DUNN-COLEMAN NIGEL | 2007-01-04 | — | — | US | disclosed |
| US-20060292625-A1 | Novel human leucine-rich repeat domain containing protein HLLRCR-1 | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-28 | — | — | US | disclosed |
| US-7153678-B2 | Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof | BRISTOL-MYERS SQUIBB (US) | 2006-12-26 | — | — | US | disclosed |
| US-7153952-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2006-12-26 | — | — | US | disclosed |
| US-20060286111-A1 | TUMOR NECROSIS FACTOR RELATED LIGAND | BIOGEN IDEC MA INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060286031-A1 | Modulators of tissue regeneration | BIOGEN IDEC MA INC. | 2006-12-21 | — | — | US | disclosed |
| US-7151171-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2006-12-19 | — | — | US | disclosed |
| WO-2006128678-A1 | MOLECULAR GLUE | UNIVERSITÄT REGENSBURG (DE) | 2006-12-07 | — | — | WO | disclosed |
| US-7144856-B2 | Inhibitors of dipeptidyl peptidase I | PROBIODRUG AG (DE) | 2006-12-05 | — | — | US | disclosed |
| US-20060269544-A1 | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42 | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
| CN-1867352-A | Therapeutic uses of chemokine variants | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | CN | disclosed |
| US-20060257918-A1 | Polynucleotide encoding a novel human G-protein coupled receptor variant of the relaxin receptor HGPRBMY5v1, and variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-20060257921-A1 | Novel nucleic acid molecules and polypeptides encoding baboon TAFI | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-20060257875-A1 | Affinity screening using \"one-bead-one-compound\" libraries | CARLSBERG A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| US-20060257402-A1 | Use of soluble cd164 in inflammatory and/or autoimmune disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-11-16 | — | — | US | disclosed |
| US-20060257404-A1 | Modulators of the P2Y10 receptor useful in altering T lymphocyte function | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-7135560-B1 | Vectors; cells; drug targets | SANOFI PASTEUR LIMITED (CA) | 2006-11-14 | — | — | US | disclosed |
| US-20060246051-A1 | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42 | FEDER JOHN N | 2006-11-02 | — | — | US | disclosed |
| US-20060248603-A1 | Novel fibrillin-like polypeptides | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-11-02 | — | — | US | disclosed |
| US-7129085-B2 | Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| US-7129340-B1 | Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limited/sanofi pasteur limitée (CA) | 2006-10-31 | — | — | US | disclosed |
| US-7129061-B1 | Tumor necrosis factor related ligand | BIOGEN IDEC MA INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-7129341-B1 | Identification of Candida albicans essential fungal specific genes and use thereof in antifungal drug discovery | MCGILL UNIVERSITY (CA) | 2006-10-31 | — | — | US | disclosed |
| US-7129339-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20060241020-A1 | Protein tyrosine phosphatase inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. | 2006-10-26 | — | — | US | disclosed |
| EP-1713780-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060234940-A1 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | ROYALTY PHARMA FINANCE TRUST | 2006-10-19 | — | — | US | disclosed |
| US-20060234973-A1 | Transcription factor RNA interference reagents and methods of use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
| US-7122368-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2006-10-17 | — | — | US | disclosed |
| US-7122358-B2 | Testis-specific tubulin tyrosine-ligase-like protein, BGS42 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060229272-A1 | Human G-protein coupled receptor, HGPRBMY11, and variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-12 | — | — | US | disclosed |
| US-20060228709-A1 | Novel fibulin-like polypeptides | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| US-20060228327-A1 | Cc-chemokine mutants against liver diseases | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| CN-1845752-A | Use of soluble cd164 in inflammatory and/or autoimmune disorders | APPLIED RESEARCH SYSTEMS (AN) | 2006-10-11 | — | — | CN | disclosed |
| US-7115402-B2 | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-7115731-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limited/ sanofi pasteur limiteé (CA) | 2006-10-03 | — | — | US | disclosed |
| US-7109298-B2 | Tumor necrosis factor related ligand | THE FACULTY OF MEDICINE OF THE UNIVERSITY OF GENEVA (CH) | 2006-09-19 | — | — | US | disclosed |
| US-20060204498-A1 | Novel antagonists of cxcr3-binding cxc chemokines | MERCK SERONO SA (CH) | 2006-09-14 | — | — | US | disclosed |
| US-7101962-B2 | Antibodies of the P2Y10 receptor useful in altering T lymphocyte function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-7098023-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | SANOFI PASTEUR LIMITED (CA) | 2006-08-29 | — | — | US | disclosed |
| US-7094572-B2 | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 | BRISTOL-MYERS SQUIBB (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183670-A1 | Autoantigen composition | JOSLIN DIABETES CENTER, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060183196-A1 | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, CAN-12, and variants thereof | CHEN JIAN | 2006-08-17 | — | — | US | disclosed |
| US-20060183686-A1 | NOVEL NUCLEIC ACID MOLECULES AND POLYPEPTIDES ENCODING BABOON TAFI | TAMURA JAMES K | 2006-08-17 | — | — | US | disclosed |
| US-7091331-B2 | Nucleic acid molecules and polypeptides encoding baboon TAFI | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060178315-A1 | Irreversible cysteine protease inhibitors of legumain | PROBIODRUG AG | 2006-08-10 | — | — | US | disclosed |
| US-20060177903-A1 | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 | RAMANATHAN CHANDRA S | 2006-08-10 | — | — | US | disclosed |
| US-7087725-B2 | Antibodies specifically reactive with a tumor necrosis factor related ligand | THE FACULTY OF MEDICINE OF THE UNIVERSITY OF GENEVA (CH) | 2006-08-08 | — | — | US | disclosed |
| US-7087390-B2 | CAIP-like gene family | BIOGEN IDEC MA INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-0914339-B1 | RET LIGAND 3 (RetL3) FOR STIMULATING NEURAL AND RENAL GROWTH | BIOGEN IDEC INC (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1017397-B1 | PHOTOSENSITIZER CONJUGATES FOR PATHOGEN TARGETING | GEN HOSPITAL CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7084241-B2 | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases | THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-7081530-B1 | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics | sanofi pasteur limitée (CA) | 2006-07-25 | — | — | US | disclosed |
| EP-1680120-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | Probiodrug AG (DE) | 2006-07-19 | — | — | EP | disclosed |
| US-20060154342-A1 | Acid fungal proteases | DANISCO US INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060155117-A1 | Novel preadipocyte factor-1-like polypeptides | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-07-13 | — | — | US | disclosed |
| US-7074914-B1 | Bactericides; polypeptides; genetic engineering | sanofi pasteur limitée (CA) | 2006-07-11 | — | — | US | disclosed |
| US-20060150262-A1 | Novel mucin-like polypeptides | BIENKOWSKA JADWIGA | 2006-07-06 | — | — | US | disclosed |
| US-20060147974-A1 | Novel Drosophila tumor necrosis factor class molecule (\"DmTNF\") and variants thereof | CARROLL PAMELA M | 2006-07-06 | — | — | US | disclosed |
| US-20060147973-A1 | Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01 | CHEN JIAN | 2006-07-06 | — | — | US | disclosed |
| US-20060141468-A1 | Novel notch-like polypeptides | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-06-29 | — | — | US | disclosed |
| WO-2006058720-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006059914-A1 | MODULATION OF OVULATION | AGRESEARCH LIMITED (NZ) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006059913-A1 | MODULATION OF OVULATION | AGRESEARCH LIMITED (NZ) | 2006-06-08 | — | — | WO | disclosed |
| EP-1409673-B1 | HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN, EXPRESSED PREDOMINANTELY IN SMALL INTESTINE, HLRRSI1 | BRYSTOL MYERS SQUIBB COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| US-7056737-B2 | Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2006056478-A1 | KITS AND METHODS FOR DETECTING METHYLATED DNA | KLINIKUM DER UNIVERSITÄT REGENSBURG (DE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006056480-A2 | MEANS AND METHODS FOR DETECTING METHYLATED DNA | KLINIKUM DER UNIVERSITÄT REGENSBURG (DE) | 2006-06-01 | — | — | WO | disclosed |
| US-7049096-B2 | Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1 | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060105379-A1 | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 | WU SHUJIAN | 2006-05-18 | — | — | US | disclosed |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PROBIODRUG AG | 2006-05-11 | — | — | US | disclosed |
| EP-1655367-A1 | Modulators of tissue regeneration | THE GENERAL HOSPITAL CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060094080-A1 | DNA sequence encoding enzyme obtained from filamentous fungi; fermenting cell transformed with polypeptide | GENENCOR INTERNATIONAL, INC. | 2006-05-04 | — | — | US | disclosed |
| US-7037676-B2 | Drosophila tumor necrosis factor class molecule polynucleotides and variants thereof | BRISTOL-MYERS SQUIBB (US) | 2006-05-02 | — | — | US | disclosed |
| US-7034134-B2 | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060084148-A1 | April-a novel protein with growth effects | BIOGEN, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060084140-A1 | Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY39 | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-20 | — | — | US | disclosed |
| US-20060080744-A1 | Novel chemokine-like polypeptides | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-13 | — | — | US | disclosed |
| US-20060073161-A1 | Nucleic acid and amino acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics | GENOME THERAPEUTICS | 2006-04-06 | — | — | US | disclosed |
| EP-0907735-B1 | MODULATORS OF TISSUE REGENERATION | BIOGEN IDEC INC (US) | 2006-03-01 | — | — | EP | disclosed |
| CN-1242809-C | Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cell | UNIV COLUMBIA (US) | 2006-02-22 | — | — | CN | disclosed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1623221-A2 | MODULATORS OF THE P2Y10 RECEPTOR USEFUL IN ALTERING T LYMPHOCYTE FUNCTION | Bristol-Myers Squibb Company (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| US-6994974-B1 | Intracellular amyloid-beta binding (ERAB) polypeptide-related assays | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-20060019364-A1 | Acetyl CoA carboxylase 2 sequences and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20060014180-A1 | Human phosphatase RET31, and variants thereof | JACKSON DONALD G | 2006-01-19 | — | — | US | disclosed |
| EP-1179186-B1 | METHOD FOR IDENTIFYING MODULATORS OF INTERACTING PROTEINS | UNIV MCGILL (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20060003367-A1 | Polynucleotides encoding a novel human Kupffer cell receptor protein, BGS-18 | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050271632-A1 | Methods of modulating hair growth | THE GENERAL HOSPITAL CORPORATION, A MASSACHUSETTS CORPORATION | 2005-12-08 | — | — | US | disclosed |
| EP-1591530-A2 | A tumor necrosis factor related ligand | Biogen Idec MA Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1588173-A2 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | Carlsberg A/S (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050233978-A1 | Novel inhibitors of dipeptidyl peptidase I | PROBIODRUG AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-0956351-B1 | A TUMOR NECROSIS FACTOR RELATED LIGAND | BIOGEN IDEC INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227238-A1 | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 | BRISTOL- MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050227283-A1 | Drosophila tumor necrosis factor class molecule (\"DmTNFv2\") | CARROLL PAMELA M | 2005-10-13 | — | — | US | disclosed |
| US-20050220757-A1 | consensus sequences; Rantes; CCR5 chemokine receptor antagonists; autoimmune diseases; cancer | MERCK SERONO SA (CH) | 2005-10-06 | — | — | US | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| US-6949363-B2 | Polynucleotides encoding novel human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1 | BRILSTOL-MYERS SQUIBB (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050208526-A1 | Polynucleotide encoding a novel human G-protein coupled receptor variant of the relaxin receptor, HGPRBMY5v1, and variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-20050203048-A1 | Human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1 | FEDER JOHN N (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050196753-A1 | Human coactivator-associated arginine methyltransferase 1 (hCARM1) | EXELIXIS, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050197312-A1 | Transcription factor RNA interference reagents and methods of use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176622-A1 | Secondary binding site of dipeptidyl peptidase IV (DPIV) | PROSIDION LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050171016-A1 | Thrombospondin-2 and uses thereof | THE GENERAL HOSPITAL CORPORATION, A MASSACHUSETTS CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-08-04 | — | — | US | disclosed |
| US-6924141-B2 | Methods of modulating hair growth | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050164906-A1 | Inhibitors of the Mitogen Activated Protein Kinases (MAPKs) pathway activated by Ras/Raf complex using GILZ (glucocorticoid-Induced Leucine Zipper) protein related compounds as inhibitors of Raf/Ras-mediated signal transduction; anticarcinogenic agents | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-07-28 | — | — | US | disclosed |
| US-6916631-B2 | Comprises monoclonal antibody for diagnosis and treatment of skin disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050148016-A1 | Novel human G-protein coupled receptor, HGPRBMY29sv1 polypeptides | FEDER JOHN N (US) | 2005-07-07 | — | — | US | disclosed |
| US-6913906-B2 | Flavor active modified thaumatin and monellin and methods for their production and use | BOLEN PAUL L (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1173619-B1 | IDENTIFICATION OF CANDIDA ALBICANS ESSENTIAL FUNGAL SPECIFIC GENES AND USE THEREOF IN ANTIFUNGAL DRUG DISCOVERY | UNIV MCGILL (CA) | 2005-06-29 | — | — | EP | disclosed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | disclosed |
| US-20050136404-A1 | Point mutations; recombinant vectors/molecular targets; transcription factors; vaccines; homologous recombination; computerized genome analysis | SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE (CA) | 2005-06-23 | — | — | US | disclosed |
| EP-1543023-A2 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | Prosidion Limited (GB) | 2005-06-22 | — | — | EP | disclosed |
| US-20050130286-A1 | POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-20050130265-A1 | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-06-16 | — | — | US | disclosed |
| WO-2005049027-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2005-06-02 | — | — | WO | disclosed |
| US-20050118166-A1 | Therapeutic applications for the anti-T-BAM (CD40-1) monoclonal antibody 5C8 | BIOGEN INCORPORATED | 2005-06-02 | — | — | US | disclosed |
| US-20050118629-A1 | Antibodies specifically reactive with a tumor necrosis factor related ligand | BIOGEN MA INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050118632-A1 | Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| US-20050112596-A1 | APRIL-A novel protein with growth effect | TSCHOPP JURG (CH) | 2005-05-26 | — | — | US | disclosed |
| US-20050112666-A1 | Tumor necrosis factor related ligand | BIOGEN, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20050107308-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-20050101540-A1 | STAT modulators | AMGEN INC. (US) | 2005-05-12 | — | — | US | disclosed |
| EP-1528931-A1 | METHODS FOR IMPROVING ISLET SIGNALING IN DIABETES MELLITUS AND FOR ITS PREVENTION | Prosidion Ltd. (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-6890534-B1 | Aiolos genes and polypeptides of the present invention are useful for studying, diagnosing and/or treating diseases associated with unwanted cell proliferation, e.g., leukemias or lymphomas | THE GENERAL HOSPITAL CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-6890905-B2 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2005-05-10 | — | — | US | disclosed |
| US-20050089868-A1 | Modulators of tissue regeneration | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-04-28 | — | — | US | disclosed |
| US-6884782-B2 | STAT modulators | AMGEN INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050080235-A1 | Ret ligand (RetL) for stimulating neural and renal growth | BIOGEN IDEC MA INC. | 2005-04-14 | — | — | US | disclosed |
| US-6878817-B2 | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | BOSTON HEART FOUNDATION, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050048620-A1 | Polynucleotides encoding a novel human neuronal cell adhesion protein, BGS-28, and variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-03 | — | — | US | disclosed |
| US-6861509-B1 | Antibodies to Ret and RetL3 | BIOGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6858407-B2 | Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| CN-1582149-A | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROBIODRUG AG (DE) | 2005-02-16 | — | — | CN | disclosed |
| US-20050032166-A1 | Polynucleotides encoding novel adiponectin receptor variants | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-20050026191-A1 | Polynucleotides encoding novel guanylate binding proteins (GBP's) | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-03 | — | — | US | disclosed |
| US-6849415-B2 | TRAF-3 deletion isoforms and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050014946-A1 | Substituted amino ketone compounds | PROSIDION LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| US-6844316-B2 | Inhibitors of dipeptidyl peptidase I | PROBIODRUG AG (DE) | 2005-01-18 | — | — | US | disclosed |
| EP-1053251-A4 | THE AIOLOS GENE | GEN HOSPITAL CORP (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004103293-A2 | MODULATORS OF THE P2Y10 RECEPTOR USEFUL IN ALTERING T LYMPHOCYTE FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| US-6822070-B2 | MODIFIED CD40 RECEPTOR-ASSOCIATED FACTOR 1(CRAFI) GENE PREVENTS CELL ACTIVATION | NATIONAL INSTITUTES OF HEALTH, THE | 2004-11-23 | — | — | US | disclosed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | PROSIDION LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
| US-6818214-B2 | MODULATING CELL PROLIFERATION OR APOPTOSIS COMPRISING MODULATING PSORIASTATIN ACTIVITY | THE GENERAL HOSPITAL CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6800744-B1 | USEFUL AS TARGETS FOR DETECTION/PREVENTION OF INFECTIONS | GENOME THERAPEUTICS CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6800456-B2 | PROTEASE FOR USE IN THE TREATMENT AND PREVENTION OF VIRAL DISEASE AND INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-6773881-B2 | BY MODULATING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) | THE GENERAL HOSPITAL CORPORATION | 2004-08-10 | — | — | US | disclosed |
| EP-1442049-A2 | SUBSTITUTED AMINO KETONE COMPOUNDS | Probiodrug AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-6770745-B2 | ANTIBODIES WHICH SPECIFICALLY BIND TO THE GC CHAIN OF CYTOKINE RECEPTORS | BIOGEN IDEC MA INC. | 2004-08-03 | — | — | US | disclosed |
| WO-2004062553-A2 | AFFINITY SCREENING USING “ONE-BEAD-ONE-COMPOUND” LIBRARIES | CARLSBERG A/S (DK) | 2004-07-29 | — | — | WO | disclosed |
| CN-1512868-A | Methods of preventing UVB-induced skin damage | ͨ��ҽ�ƹ�˾ | 2004-07-14 | — | — | CN | disclosed |
| EP-1434792-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | Probiodrug AG (DE) | 2004-07-07 | — | — | EP | disclosed |
| EP-1423410-A2 | PEPTIDES HAVING A C-TERMINAL HYDROXYLAMINO GROUP AS INHIBITORS OF DIPEPTIDYL PEPTIDASE I | Probiodrug AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1416932-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | Probiodrug AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1417220-A2 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS OF LEGUMAIN | Probiodrug AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-6723699-B1 | ADMINISTERING AS CHOLINERGIC AGENT TO TREAT NERVOUS SYSTEM DISORDERS | CEPHALON, INC. | 2004-04-20 | — | — | US | disclosed |
| WO-2004031374-A2 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | PROSIDION LTD. (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6712617-B2 | THERAPY OF ULTRAVIOLET-B (UVB) IRRADIATION RESULTS SUCH AS FORMATION OF WRINKLES BY INHIBITING ANGIOGENESIS IN THE SKIN | THE GENERAL HOSPITAL CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-20040058876-A1 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | PROSIDION LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1399470-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1399471-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1399469-A2 | PEPTIDE STRUCTURES USEFUL FOR COMPETITIVE MODULATION OF DIPEPTIDYL PEPTIDASE IV CATALYSIS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004017989-A1 | METHODS FOR IMPROVING ISLET SIGNALING IN DIABETES MELLITUS AND FOR ITS PREVENTION | PROSIDION LTD. (GB) | 2004-03-04 | — | — | WO | disclosed |
| US-6699703-B1 | NEW TARGETS FOR ANTIMICROBIAL THERAPIES, INCLUDING, VACCINES AND ANTIBIOTICS | GENOME THERAPEUTICS CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6693076-B1 | ENHANCING SURVIVAL OF NEURONAL CELLS AT RISK OF DYING DUE TO INJURY OR EPILEPSY | CEPHALON, INC. | 2004-02-17 | — | — | US | disclosed |
| US-6692934-B1 | FOR TARGETING DRUGS TO SPECIFIC ORGANS AND FOR MODULATING THE CONCENTRATION OF ENDOGENOUS SUBSTRATES | BRISTOL-MYERS SQUIBB CO. | 2004-02-17 | — | — | US | disclosed |
| US-6686450-B1 | AN ISOLATED POLYPEPTIDE, CABIN 1, MODULATES TRANSCRIPTION FACTOR ACTIVITY BY INHIBITION OF SERINE/THREONINE PHOSPHATASE (CALCINERIUM) ACTIVITY; USE IN THERAPY AND IDENTIFICATION OF AUTOIMMUNE DISEASE, ALLERGIES, TRANSPLANT GRAFT REJECTION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-02-03 | — | — | US | disclosed |
| US-6682911-B1 | LAMININ 12 WAS ISOLATED FROM HUMAN PLACENTAL CHORIONIC VILLI | THE GENERAL HOSPITAL CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6677135-B1 | ISOLATED NUCLEIC ACID ENCODING POLYPEPTIDE SELECTED FROM SEQUENCE IDENTIFICATION NUMBERS 17 AND 21 | BIOGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6673910-B1 | POLYPEPTIDE FROM MORACELLA; GENETIC ENGINEERING AND EXPRESSION; ANTIBODIES; INFECTION PREVENTION | GENOME THERAPEUTICS CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-6664385-B1 | Kidney injury-related molecules | BIOGEN, INC. | 2003-12-16 | — | — | US | disclosed |
| US-6656705-B1 | Nucleic acid, of given sequence, encoding a epidermal protein; use in diagnosis and treatment of disorders related to skin, hair, tissue adhesion and keratinocyte activity | THE GENERAL HOSPITAL CORPORATION | 2003-12-02 | — | — | US | disclosed |
| US-6642041-B2 | Proteolytic enzymes; m edical diagnosis; drug screening; treatment of juvenile amyotrophic lateral sclerosis | BRISTOL-MEYERS SQUIBB COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-6632923-B1 | Polypeptide; vaccines | BOSTON HEART FOUNDATION, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-6617156-B1 | Encoding a polypeptide; use in detection, prevention and treatment of bacterial infections | GENOME THERAPEUTICS CORPORATION | 2003-09-09 | — | — | US | disclosed |
| US-6610836-B1 | Isolated nucleic acid molecule encoding polypeptide of given sequence; can use as components in antibacterial vaccines | GENOME THERAPEUTICS CORPORATION | 2003-08-26 | — | — | US | disclosed |
| US-6605709-B1 | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics | GENOME THERAPEUTICS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PROSIDION LIMITED (GB) | 2003-07-17 | — | — | US | disclosed |
| US-20030119736-A1 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| US-20030119738-A1 | Novel inhibitors of dipeptidyl peptidase I | PROBLODRUG AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6583275-B1 | Nucleotide sequences coding polypeptied for use in the treatment, diagnosis and prevention of bacterial infection | GENOME THERAPEUTICS CORPORATION | 2003-06-24 | — | — | US | disclosed |
| US-6566074-B1 | Modulation of cell attachement; obtain cells, administering antibody that binds to a syndecan domain on cell surface, monitor cell attachment, evaluate cell for cancer | THE GENERAL HOSPITAL CORPORATION | 2003-05-20 | — | — | US | disclosed |
| US-6566489-B1 | Animal model for use as tool in human therapeutics and diagnostics | THE GENERAL HOSPITAL CORPORATION | 2003-05-20 | — | — | US | disclosed |
| WO-2003040174-A2 | SUBSTITUTED AMINO KETONE COMPOUNDS | PROBIODRUG AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| US-6562958-B1 | Nucleotide sequences coding polypeptide for use in the treatment and prevention of infections | GENOME THERAPEUTICS CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-6558663-B1 | Promoting tolerance and inhibiting natural killer cell mediated attack in human recipient to a swine graft | THE GENERAL HOSPITAL CORPORATION | 2003-05-06 | — | — | US | disclosed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003022871-A2 | PEPTIDES HAVING A C- TERMINAL HYDROXYLAMINO GROUP AS INHIBITORS OF DIPEPTIDYL PEPTIDASE I | PROBIODRUG AG (DE) | 2003-03-20 | — | — | WO | disclosed |
| US-6534035-B1 | In vivo imaging localization using labeled alpha-2 antiplasmin polypeptide | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-03-18 | — | — | US | disclosed |
| US-6528634-B1 | Nucleic acid sequence of the Ikaros family of transcriptional regulators of hematopoiesis, particularly with regard to B-and T-cell lymphocyte development. | THE GENERAL HOSPITAL CORPORATION | 2003-03-04 | — | — | US | disclosed |
| WO-2003016335-A2 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS OF LEGUMAIN | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| US-6518052-B1 | Nucleic acid and amino acid sequence of a human Pif-1 type helicase. The invention also provides methods of screening for compounds that modulate the activity of human Pif-1 type helicase, as well as methods for affecting viability of a | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-11 | — | — | US | disclosed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002593-A2 | PEPTIDE STRUCTURES USEFUL FOR COMPETITIVE MODULATION OF DIPEPTIDYL PEPTIDASE IV CATALYSIS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| US-6489136-B1 | CANCER DIAGNOSIS; POLYPEPTIDE ENCODED WITH BASIC HELIX-LOOP-HELIX-LOOP-LEUCINE ZIPPER MOTIF; GENETIC ENGINEERING AND EXPRESSION | THE GENERAL HOSPITAL CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020151504-A1 | STAT modulators | TULARIK INC. | 2002-10-17 | — | — | US | disclosed |
| US-6465424-B1 | COMPRISING A PURIFIED POLYPEPTIDE THE AMINO ACID SEQUENCE OF WHICH COMPRISES THE PRE-ACTIVATION DOMAIN FROM PLASMINOGEN AND AT LEAST ONE KRINGLE FROM PLASMINOGEN | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-15 | — | — | US | disclosed |
| US-6462070-B1 | POLYLYSINE COUPLED WITH A HISTATIN TARGETING MOIETY AND A PORPHYRIN; TREATING ORAL CAVITIES | THE GENERAL HOSPITAL CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-6455683-B1 | NUCLEOTIDESEQUENCES CODING PROTEIN FOR USE IN THE PREVETION AND TREATMENT OF INFECTIOUS, INFLAMMATORY AND ALLERGIC DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6426331-B1 | IMMUNOLOGY CONTROL; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | TULARIK INC. | 2002-07-30 | — | — | US | disclosed |
| US-6423824-B1 | CAIP-like gene family | BIOGEN, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1222288-A2 | HUMAN PIF1 DNA HELICASE AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6410710-B1 | NUCLEOTIDES SEQUENCES CODING PROTEIN FOR USE IN TREATMENT OF AUTOIMMUNE RESPONSE DEFECTS | THE TRUSTEES OF THE UNIVERSITY IN THE CITY OF NEW YORK | 2002-06-25 | — | — | US | disclosed |
| WO-2002038107-A2 | STAT MODULATORS | TULARIK INC. (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-1058500-A4 | THE HELIOS GENE | GEN HOSPITAL CORP (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1066051-A4 | SCIELLIN AND USES THEREOF | GEN HOSPITAL CORP (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6380370-B1 | GENETIC SEQUENCE; NUCLEOTIDE SEQUENCE | GENOME THERAPEUTICS CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-1183363-A2 | METHODS FOR REGULATING PROTEIN CONFORMATION USING MOLECULAR CHAPERONES | Roche Diagnostics GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| EP-1179186-A2 | METHOD FOR IDENTIFYING MODULATORS OF INTERACTING PROTEINS | McGill University (CA) | 2002-02-13 | — | — | EP | disclosed |
| EP-1173619-A2 | IDENTIFICATION OF CANDIDA ALBICANS ESSENTIAL FUNGAL SPECIFIC GENES AND USE THEREOF IN ANTIFUNGAL DRUG DISCOVERY | McGill University (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6340459-B1 | ADMINISTERING TO AGENT CAPABLE OF INHIBITING INTERACTION BETWEEN CD40 LIGAND AND THE CELLS TO INHIBIT ACTIVATION OF THE CELLS IN THERAPY OF REPERFUSION INJURY, IN AN NON-TRANSPLANT RECIPIENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2002-01-22 | — | — | US | disclosed |
| EP-1170993-A1 | NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING 4E-BP1 | McGill University (CA) | 2002-01-16 | — | — | EP | disclosed |
| US-6333186-B1 | GENETICALLY ENGINEERED ENZYMATIC POLYPEPTIDES; FOR USE AS DIAGNOSTIC TOOLS IN DETERMINING CRYSTAL STRUCTURES IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, X-RAY CRYSTALLOGRAPHY, AND SCREENING FOR ENZYME INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2001-12-25 | — | — | US | disclosed |
| EP-0956030-A4 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40L) TECHNOLOGY TO TREAT DISEASES INVOLVING SMOOTH MUSCLE CELLS | UNIV COLUMBIA (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6323027-B1 | Common gamma chain monoclonal antibody blocking agents | BIOGEN, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0880597-A4 | THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5c8 | UNIV COLUMBIA (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001083517-A1 | STAT4 AND STAT6 BINDING DIPEPTIDE DERIVATIVES | TULARIK INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-1149909-A1 | Methods for regulating protein conformation using molecular chaperones | BOEHRINGER MANNHEIM GMBH (DE) | 2001-10-31 | — | — | EP | disclosed |
| US-6310040-B1 | FOR PROMOTING THE SURVIVAL OF PHOTORECEPTORS IN A MAMMAL | CEPHALON, INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2001067862-A1 | ADRENERGIC RECEPTOR OVEREXPRESSION IN AIRWAY TISSUES FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES | UNIVERSITY OF CINCINNATI (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-0723974-B1 | Derivatives of mercaptoalkanoyldipeptides, their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-08-16 | — | — | EP | disclosed |
| US-6268479-B1 | HUMAN ENDOPLASMIC RETICULUM ASSOCIATED POLYPEPTIDE OF DEFINED AMINO ACID SEQUENCE; TREATING ASSOCIATED NERVOUS SYSTEM DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2001-07-31 | — | — | US | disclosed |
| WO-2001030986-A2 | HUMAN PIF1 DNA HELICASE AND USES THEREOF | BRISTOL-MYERS SQUIBB CO. (US) | 2001-05-03 | — | — | WO | disclosed |
| EP-0856005-A4 | THE AIOLOS GENE | GEN HOSPITAL CORP (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1066051-A1 | SCIELLIN AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6171800-B1 | MAKING A CD2 ASSOCIATED INTRACELLULAR POLYPEPTIDE WHICH BINDS TO THE INTRACELLULAR DOMAIN OF CD2 BY ALTERING THE AMINO ACID SEQUENCE; FOR SCREENING COMPOUNDS TO BE USED AS IMMUNOSUPPRESSANTS AND ANTIPROLIFERATIVE AGENTS | BIOGEN, INC. | 2001-01-09 | — | — | US | disclosed |
| EP-1058500-A1 | THE HELIOS GENE | THE GENERAL HOSPITAL CORPORATION (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000071723-A2 | METHODS FOR REGULATING PROTEIN CONFORMATION USING MOLECULAR CHAPERONES | ROCHE DIAGNOSTICS GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
| US-6153593-A | Laminin 5 and the formation of basement membrane structure | THE GENERAL HOSPITAL CORPORATION (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000070351-A2 | PROTEIN-PROTEIN INTERACTIONS AND METHODS FOR IDENTIFYING THEM | MCGILL UNIVERSITY (CA) | 2000-11-23 | — | — | WO | disclosed |
| EP-1053251-A1 | THE AIOLOS GENE | THE GENERAL HOSPITAL CORPORATION (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000068420-A2 | IDENTIFICATION OF CANDIDA ALBICANS ESSENTIAL FUNGAL SPECIFIC GENES AND USE THEREOF IN ANTIFUNGAL DRUG DISCOVERY | MCGILL UNIVERSITY (CA) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000060932-A1 | NON-HUMAN TRANSGENIC ANIMAL WHOSE GERM CELLS AND SOMATIC CELLS CONTAIN A KNOCKOUT MUTATION IN DNA ENCODING 4E-BP1 | MCGILL UNIVERSITY (CA) | 2000-10-19 | — | — | WO | disclosed |
| CN-1057097-C | Chimeric proteins which block complement activation | CYTOMED INC (US) | 2000-10-04 | — | — | CN | disclosed |
| US-6120765-A | PURIFIED PEPTIDE | SHISEIDO CO. LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-1034187-A1 | $i(IN VITRO) AND $i(IN VIVO) GROWTH-PROMOTING PROTEINS AND PEPTIDES FOR KIDNEY EPITHELIAL CELLS | ARCH DEVELOPMENT CORPORATION (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-1027431-A2 | APRIL- A NOVEL PROTEIN WITH GROWTH EFFECTS | Apotech R&D S.A. (CH) | 2000-08-16 | — | — | EP | disclosed |
| EP-0857174-A4 | UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS | GEN HOSPITAL CORP (US) | 2000-05-31 | — | — | EP | disclosed |
| CN-1255063-A | Photosensitizer conjugates targeting pathogens | GEN HOSPITAL CORP (US) | 2000-05-31 | — | — | CN | disclosed |
| CN-1246799-A | Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof | ASTRA AB (SE) | 2000-03-08 | — | — | CN | disclosed |
| US-6030833-A | GENETICALLY ENGINEERED CELL WHICH INCLUDES ONE OR MORE OF A HUMAN HUMAN LEUKOCYTE ANTIGEN A, B, C, OR G TRANSGENE; FOR ORGAN TRANSPLANTS WITH IMMUNOSUPPRESSION OF HUMAN NATURAL KILLER CELL MEDIATED ATTACK | THE GENERAL HOSPITAL (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0956030-A1 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40L) TECHNOLOGY TO TREAT DISEASES INVOLVING SMOOTH MUSCLE CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-11-17 | — | — | EP | disclosed |
| EP-0956351-A1 | A TUMOR NECROSIS FACTOR RELATED LIGAND | BIOGEN, INC. (US) | 1999-11-17 | — | — | EP | disclosed |
| CN-1235513-A | Nucleic acid and amino acid sequences ralating to helicobacter pylori and vaccine compositions thereof | ASTRA AB (SE) | 1999-11-17 | — | — | CN | disclosed |
| EP-0768821-A4 | pp60PIK : A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER INC (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0781326-A4 | THE IRS FAMILY OF GENES | JOSLIN DIABETES CENTER INC (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999048521-A1 | SCIELLIN AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
| EP-0871463-A4 | REGULATION OF EATING BEHAVIOR | JOSLIN DIABETES CENTER INC (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1999043208-A1 | THE HELIOS GENE | THE GENERAL HOSPITAL CORPORATION (US) | 1999-09-02 | — | — | WO | disclosed |
| CN-1227494-A | Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cell | UNIV COLUMBIA (US) | 1999-09-01 | — | — | CN | disclosed |
| WO-1999040930-A1 | SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES | CENTER FOR BLOOD RESEARCH, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040111-A1 | THE AIOLOS GENE | THE GENERAL HOSPITAL CORPORATION (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999026974-A1 | IN VITRO AND IN VIVO GROWTH-PROMOTING PROTEINS AND PEPTIDES FOR KIDNEY EPITHELIAL CELLS | ARCH DEVELOPMENT CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5908829-A | Use of MCP-1 for inducing ripening of the cervix | MEDICAL RESEARCH COUNCIL (GB) | 1999-06-01 | — | — | US | disclosed |
| WO-1999012965-A2 | APRIL- A NOVEL PROTEIN WITH GROWTH EFFECTS | BIOGEN, INC. (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5851528-A | Methods of inhibiting complement activation | CYTOMED, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0880597-A1 | THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5c8 | The Trustees of Columbia University in the City of New York (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0874637-A1 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40L) TECHNOLOGY TO TREAT INFLAMMATORY KIDNEY DISEASES | The Trustees of Columbia University in the City of New York (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0871463-A1 | REGULATION OF EATING BEHAVIOR | THE JOSLIN DIABETES CENTER, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0857174-A1 | UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-08-12 | — | — | EP | disclosed |
| EP-0856005-A1 | THE AIOLOS GENE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-08-05 | — | — | EP | disclosed |
| EP-0726945-A4 | B1k CHAIN OF LAMININ AND METHODS OF USE | GEN HOSPITAL CORP (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5776897-A | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| CN-1186516-A | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics | ASTRA AB (SE) | 1998-07-01 | — | — | CN | disclosed |
| US-5767075-A | ADMINISTERING A RAS-BINDING PEPTIDE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5763571-A | AMINO ACID SEQUENCES WHICH INHIBIT BINDING | THE GENERAL HOSPITAL CORPORATION (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0842266-A1 | TRANSGENIC SWINE AND SWINE CELLS HAVING HUMAN HLA GENES | THE GENERAL HOSPITAL CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5736337-A | EVALUATING ANTIPROLIFERATIVE COMPOUND COMPRISING CONTACTING WITH RAS-BINDING FRAGMENT OF RAF AND DETERMINING ABILITY TO BIND TO SAID FRAGMENT | THE GENERAL HOSPITAL CORPORATION (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997034473-A9 | CRAF1 (TRAF-3) ISOFORMS AND USES THEREOF | — | 1998-04-02 | — | — | WO | disclosed |
| US-5728579-A | THERAPEUTIC TARGETS FOR TREATMENT OF BREAST CANCER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1998005783-A1 | A TUMOR NECROSIS FACTOR RELATED LIGAND | BIOGEN, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1998001145-A1 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40L) TECHNOLOGY TO TREAT DISEASES INVOLVING SMOOTH MUSCLE CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-01-15 | — | — | WO | disclosed |
| US-5703045-A | NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1997019098-A9 | NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO HELICOBACTER PYLORI FOR DIAGNOSTICS AND THERAPEUTICS | — | 1997-11-06 | — | — | WO | disclosed |
| US-5679546-A | CULTURE PRODUCT | CYTOMED, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0798000-A2 | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1997026000-A9 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40-L) TECHNOLOGY TO TREAT INFLAMMATORY KIDNEY DISEASES______________________________________ | — | 1997-09-04 | — | — | WO | disclosed |
| EP-0476044-B1 | Use of IGF1 or IGF2 for the manufacture of a medicament in the treatment of amyotrophic lateral sclerosis | CEPHALON INC (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5652214-A | ENHANCING SURVIVAL OF NEURONAL CELLS IN HEAD AND SPINAL CORD AFTER INJURY, ALSO TREATMENT OF AGING, ALZHEIMER*S, STROKE, EPILEPSY | CEPHALON, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1997026000-A1 | THERAPEUTIC APPLICATIONS OF T-BAM (CD40-L) TECHNOLOGY TO TREAT INFLAMMATORY KIDNEY DISEASES______________________________________ | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0781326-A1 | THE IRS FAMILY OF GENES | THE JOSLIN DIABETES CENTER, INC. (US) | 1997-07-02 | — | — | EP | disclosed |
| US-5639651-A | ANTITUMOR AGENTS; MEDICAL DIAGNOSIS | THE GENERAL HOSPITAL CORPORATION (US) | 1997-06-17 | — | — | US | disclosed |
| WO-1997010841-A9 | ANTIANGIOGENIC PROPERTIES OF ENDOTHELIAL-MONOCYTE ACTIVATING POLYPEPTIDE II | — | 1997-06-12 | — | — | WO | disclosed |
| WO-1997020063-A1 | THEREAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5c8 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-06-05 | — | — | WO | disclosed |
| WO-1997008308-A9 | BATTEN DISEASE GENE | — | 1997-05-15 | — | — | WO | disclosed |
| WO-1997014714-A1 | THE AIOLOS GENE | THE GENERAL HOSPITAL CORPORATION (US) | 1997-04-24 | — | — | WO | disclosed |
| WO-1997014425-A1 | TWO NOVEL GENES FROM PSORIATIC EPIDERMIS: PSORIASTATIN TYPE I AND PSORIASTATIN TYPE II | THE GENERAL HOSPITAL CORPORATION (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0768821-A1 | pp60PIK : A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | THE JOSLIN DIABETES CENTER, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1997012905-A1 | UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997010841-A1 | ANTIANGIOGENIC PROPERTIES OF ENDOTHELIAL-MONOCYTE ACTIVATING POLYPEPTIDE II | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-03-27 | — | — | WO | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
| WO-1997008308-A1 | BATTEN DISEASE GENE | THE GENERAL HOSPITAL CORPORATION (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997006241-A1 | TRANSGENIC SWINE AND SWINE CELLS HAVING HUMAN HLA GENES | THE GENERAL HOSPITAL CORPORATION (US) | 1997-02-20 | — | — | WO | disclosed |
| EP-0604605-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1997-01-29 | — | — | EP | disclosed |
| CN-1138863-A | Chimeric proteins which block complement activation | CYTOMED INC (US) | 1996-12-25 | — | — | CN | disclosed |
| WO-1996039162-A1 | REGULATION OF EATING BEHAVIOR | JOSLIN DIABETES CENTER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5582995-A | ADMINISTERING PEPTIDES OR PEPTIDE FRAGMENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0726945-A1 | B1k CHAIN OF LAMININ AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0723974-A1 | Derivatives of mercaptoalkanoyldipeptides, their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-07-31 | — | — | EP | disclosed |
| US-5530124-A | Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1996010629-A1 | THE IRS FAMILY OF GENES | JOSLIN DIABETES CENTER, INC. (US) | 1996-04-11 | — | — | WO | disclosed |
| WO-1995034201-A1 | pp60PIK: A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
| EP-0670729-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1995011972-A1 | B1k CHAIN OF LAMININ AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1995006657-A1 | INTERLEUKIN-10 AND IMMUNOSUPPRESSION | THE GENERAL HOSPITAL CORPORATION (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1994025044-A1 | CALCITONIN GENE-RELATED PEPTIDE-INDUCED TOLERANCE | THE GENERAL HOSPITAL CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0476044-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | — | 1992-07-01 | — | — | EP | disclosed |
| EP-0476044-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0476044-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234973-A1 | Transcription factor RNA interference reagents and methods of use thereof | SNRPE, SNRPF, DDX21 | KCNH2 4803/4885SCN3A 3151/4885DPP4 3981/4885 |
| US-20060234940-A1 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | DPP4, DPP3, DPP7 | KCNH2 3775/4885SCN3A 1085/4885DPP4 1/4885 |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | DPP4, DPP3, DNPEP | KCNH2 3577/4885SCN3A 2196/4885DPP4 1/4885 |
| US-12577548-B2 | Alpha-amylase combinatorial variants | AMY1A, AMY2A, PRKCSH | KCNH2 3028/4885SCN3A 312/4885DPP4 310/4885 |
| US-20050032166-A1 | Polynucleotides encoding novel adiponectin receptor variants | ADIPOR1, ADIPOR2, FABP4 | KCNH2 4230/4885SCN3A 1207/4885DPP4 297/4885 |
| US-20050107308-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | KCNH2 2314/4885SCN3A 1212/4885DPP4 1/4885 |
| US-20050227238-A1 | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 | GPR174, GPR84, GPR68 | KCNH2 2737/4885SCN3A 1457/4885DPP4 1375/4885 |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885DPP4 898/4885 |
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | KCNH2 3946/4885SCN3A 797/4885DPP4 3/4885 |
| US-20080153892-A1 | Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | KCNH2 2030/4885SCN3A 634/4885DPP4 2049/4885 |
| US-20240358820-A1 | PROTOPARVOVIRUS COMPOSITIONS COMPRISING A PROTOPARVOVIRUS VARIANT VP1 CAPSID POLYPEPTIDE AND RELATED METHODS | GPKOW, CDV3, TIA1 | KCNH2 3596/4885SCN3A 1983/4885DPP4 1071/4885 |
| US-20060178315-A1 | Irreversible cysteine protease inhibitors of legumain | LGMN, SERPINB1, SERPINA2 | KCNH2 4861/4885SCN3A 3639/4885DPP4 944/4885 |
| US-12383615-B2 | Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods | GPKOW, CDV3, TIA1 | KCNH2 3596/4885SCN3A 1983/4885DPP4 1071/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885DPP4 898/4885 |
| US-20070026448-A1 | Polynucleotide encoding a novel human G-protein coupled receptor, HBPRBMY39 | GPR39, GPR139, GIPR | KCNH2 3311/4885SCN3A 2033/4885DPP4 1743/4885 |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | KCNH2 477/4885SCN3A 1353/4885DPP4 60/4885 |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | KCNH2 4720/4885SCN3A 3765/4885DPP4 1159/4885 |
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PREP, BACE1, BCHE | KCNH2 625/4885SCN3A 2266/4885DPP4 148/4885 |
| US-20150183848-A1 | TREATMENT OF lge-MEDIATED DISEASE | CD2, CD22, CPA3 | KCNH2 3574/4885SCN3A 574/4885DPP4 926/4885 |
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PEPD, DNPEP, ANPEP | KCNH2 3567/4885SCN3A 1850/4885DPP4 4/4885 |
| US-20080064094-A1 | Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof | GIPR, GPR39, MRGPRX2 | KCNH2 2598/4885SCN3A 1471/4885DPP4 882/4885 |
| US-12559738-B2 | Glucoamylase and methods of use thereof | MGAM, MGAM2, PRKCSH | KCNH2 3664/4885SCN3A 2229/4885DPP4 478/4885 |
| US-20080221305-A1 | Polynucleotides encoding novel adiponectin receptor variants | ADIPOR1, ADIPOR2, FABP4 | KCNH2 4230/4885SCN3A 1207/4885DPP4 297/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885DPP4 898/4885 |
| US-20250288692-A1 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | KCNQ4, KCNQ1, KCNJ4 | KCNH2 23/4885SCN3A 47/4885DPP4 1361/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | KCNH2 3613/4885SCN3A 2658/4885DPP4 343/4885 |
| US-20040058876-A1 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | DPP4, DPP3, DPP7 | KCNH2 3775/4885SCN3A 1085/4885DPP4 1/4885 |
| US-20060229272-A1 | Human G-protein coupled receptor, HGPRBMY11, and variants thereof | GNB1, GRK4, GRK5 | KCNH2 3813/4885SCN3A 1758/4885DPP4 2654/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | KCNH2 4720/4885SCN3A 3765/4885DPP4 1159/4885 |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | HIF1AN, HIF1A, EGLN3 | KCNH2 1582/4885SCN3A 1347/4885DPP4 975/4885 |
| US-20050208526-A1 | Polynucleotide encoding a novel human G-protein coupled receptor variant of the relaxin receptor, HGPRBMY5v1, and variants thereof | RXFP1, RXFP4, GIPR | KCNH2 2048/4885SCN3A 1471/4885DPP4 1257/4885 |
| US-20160215036-A1 | STABILIZED POLYPEPTIDE INSULIN RECEPTOR MODULATORS | GLP1R, RXFP1, SCTR | KCNH2 4429/4885SCN3A 1747/4885DPP4 281/4885 |
| US-12509670-B2 | Glucoamylase and methods of use thereof | MGAM, AGL, MAN2A1 | KCNH2 1420/4885SCN3A 473/4885DPP4 332/4885 |
| US-20060155117-A1 | Novel preadipocyte factor-1-like polypeptides | FABP4, APMAP, PLIN1 | KCNH2 4794/4885SCN3A 3386/4885DPP4 434/4885 |
| US-20060105379-A1 | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 | MMP3, NASP, MMP11 | KCNH2 4481/4885SCN3A 1368/4885DPP4 326/4885 |
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | FGB, SERPINC1, ECE1 | KCNH2 4070/4885SCN3A 3957/4885DPP4 107/4885 |
| US-20090297470-A1 | REMEDIES FOR ISCHEMIA | DPP4, GIPR, DPP3 | KCNH2 3083/4885SCN3A 3680/4885DPP4 1/4885 |
| US-20180354918-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, MDM4 | KCNH2 4867/4885SCN3A 4683/4885DPP4 3921/4885 |
| US-20230212606-A1 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | KCNQ4, KCNQ1, KCNJ4 | KCNH2 23/4885SCN3A 47/4885DPP4 1361/4885 |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, GPR119 | KCNH2 1908/4885SCN3A 1888/4885DPP4 359/4885 |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | KCNH2 3698/4885SCN3A 4046/4885DPP4 176/4885 |
| US-20050014946-A1 | Substituted amino ketone compounds | GPR119, GLS, GCKR | KCNH2 41/4885SCN3A 893/4885DPP4 999/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KCNH2 2405/4885SCN3A 1465/4885DPP4 898/4885 |
| US-20080293618-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP3, DPP9 | KCNH2 4372/4885SCN3A 3478/4885DPP4 1/4885 |
| US-20050118632-A1 | Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b | RNPEP, CPB1, TMPRSS15 | KCNH2 4515/4885SCN3A 2386/4885DPP4 72/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | KCNH2 651/4885SCN3A 2418/4885DPP4 1133/4885 |
| US-20100048467-A1 | Cystine-Knot Fold Cytokine | CXCL10, CCL2, CTH | KCNH2 665/4885SCN3A 1902/4885DPP4 4297/4885 |
| US-20190093089-A1 | METHODS AND COMPOSITIONS RELATED TO THIOESTERASE ENZYMES | LYPLA1, LYPLA2, ACOT7 | KCNH2 4385/4885SCN3A 3481/4885DPP4 1934/4885 |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PREP, BACE1, BCHE | KCNH2 449/4885SCN3A 2130/4885DPP4 227/4885 |
| US-12553883-B2 | Methods and uses of microbiome compositions | GYS1, GYS2, GLS | KCNH2 4035/4885SCN3A 4290/4885DPP4 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.